Clofarabine – Uses, Dosage, Side Effects, Interaction Clofarabine is a purine analog and antineoplastic agent used in the therapy of acute lymphoblastic leukemia (ALL) in children. Clofarabine is associated with frequent transient serum enzyme elevations during therapy, but they are usually asymptomatic and transient and it has only rarely been implicated in causing clinically apparent acute liver injury with jaundice. Clofarabine is a second-generation purine nucleoside analog with antineoplastic activity. Clofarabine is phosphorylated intracellularly to the cytotoxic active 5′-triphosphate metabolite, which inhibits the enzymatic activities of ribonucleotide reductase and DNA polymerase, resulting in the inhibition of DNA repair and synthesis of DNA and RNA. This nucleoside analog also disrupts mitochondrial function and membrane integrity, resulting in the release of pro-apoptotic factors, including cytochrome C and apoptotic-inducing factors, which activate apoptosis. Clofarabine is a purine nucleoside analog consisting of a 6-amino-2-chloropurin-9-yl group attached to the 1beta position of 2′-deoxy-2′-fluoro-D-arabinofuranose. It is metabolized intracellularly to the active 5′-triphosphate metabolite, which inhibits DNA synthesis is and so stops the growth of cancer cells. Clofarabine is used as an antimetabolite antineoplastic agent in the treatment of relapsed or refractory acute lymphoblastic leukemia. It has a role as an antineoplastic agent and an antimetabolite. It is an organofluorine compound and a member of adenosines. Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in pediatrics to treat a type of leukemia called relapsed or refractory acute lymphoblastic leukemia (ALL), only after at least two other types of treatment have failed. It is not known if the drug extends the life expectancy. Its potential use in acute myeloid leukemia (AML) and juvenile myelomonocytic leukemia (JMML) has been investigated. Mechanism of Action Clofarabine is metabolized intracellularly to the active 5′-monophosphate metabolite by deoxycytidine kinase and 5′-triphosphate metabolite by mono- and di-phospho-kinases. This metabolite inhibits DNA synthesis through an inhibitory action on ribonucleotide reductase, and by terminating DNA chain elongation and inhibiting repair through competitive inhibition of DNA polymerases. This leads to the depletion of the intracellular deoxynucleotide triphosphate pool and the self-potentiation of clofarabine triphosphate incorporation into DNA, thereby intensifying the effectiveness of DNA synthesis inhibition. The affinity of clofarabine triphosphate for these enzymes is similar to or greater than that of deoxyadenosine triphosphate. In preclinical models, clofarabine has demonstrated the ability to inhibit DNA repair by incorporation into the DNA chain during the repair process. Clofarabine 5′-triphosphate also disrupts the integrity of the mitochondrial membrane, leading to the release of the pro-apoptotic mitochondrial proteins, cytochrome C, and apoptosis-inducing factor, leading to programmed cell death. Clofarabine is a purine nucleoside antimetabolite that differs from other purine nucleoside analogs by the presence of chlorine in the purine ring and fluorine in the ribose moiety. Clofarabine seems to interfere with the growth of cancer cells, which are eventually destroyed. Since the growth of normal body cells may also be affected by clofarabine, other effects also occur. Clofarabine prevents cells from making DNA and RNA by interfering with the synthesis of nucleic acids, thus stopping the growth of cancer cells. Indications For the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphocytic (lymphoblastic) leukemia after at least two prior regimens. It is designated as an orphan drug by the FDA for this use. Treatment of acute lymphoblastic leukemia (ALL) in pediatric patients who have relapsed or are refractory after receiving at least two prior regimens and where there is no other treatment option anticipated to result in a durable response. Safety and efficacy have been assessed in studies of patients ≤ 21 years old at initial diagnosis. Clofarabine is approved to treat Acute lymphoblastic leukemia that has recurred (come back) or is refractory (does not respond to treatment) in children and young adults aged 1 to 21 years who have already had at least two other types of treatment. Refractory Acute Lymphoblastic Leukemia (ALL) Refractory Acute Myeloid Leukemia (AML) Relapsed Acute Lymphoblastic Leukemia (ALL) Refractory Langerhans cell histiocytosis Use in Cancer Clofarabine is approved to treat: Acute lymphoblastic leukemia that has recurred (come back) or is refractory (does not respond to treatment) in children and young adults aged 1 to 21 years who have already had at least two other types of treatment. Clofarabine is also being studied in the treatment of other types of cancer. Contraindications a bacterial infection opportunistic fungal infection dehydration decreased function of bone marrow anemia decreased blood platelets low levels of a type of white blood cell called neutrophils capillary leak syndrome, is a condition where fluid leaks out of small blood vessels low blood pressure bleeding inflammation of the small and large intestine liver problems the high amount of bilirubin in the blood abnormal liver function tests pregnancy a patient who is producing milk and breastfeeding sepsis chronic kidney disease stage 3A (moderate) chronic kidney disease stage 3B (moderate) an increased risk of developing an uncommon viral infection called an opportunistic infection Dosage Strengths: 1 mg/mL Acute Lymphoblastic Leukemia 18 to less than 22 years: 52 mg/m2 IV over 2 hours daily for 5 consecutive days of a 28-day cycle; repeat every 2 to 6 weeks Subsequent cycles should begin no sooner than 14 days from day 1 of the previous cycle. Subsequent cycles may be administered when the ANC is greater than or equal to 750/mm3. Provide supportive care, such as IV fluids, antihyperuricemics, and alkalinization of urine throughout therapy to reduce the risk of tumor lysis and other adverse events. Monitor renal, hepatic, and cardiac function during therapy. Monitor patients taking medications known to affect blood pressure. Discontinue therapy if hypotension develops during the 5 days of administration. Acute Lymphoblastic Leukemia 1 year and older: 52 mg/m2 IV over 2 hours daily for 5 consecutive days of a 28-day cycle; repeat every 2 to 6 weeks Subsequent cycles should begin no sooner than 14 days from day 1 of the previous cycle. Subsequent cycles may be administered when the ANC is greater than or equal to 750/mm3. Provide supportive care, such as IV fluids, antihyperuricemics, and alkalinization of urine throughout therapy to reduce the risk of tumor lysis and other adverse events. Monitor renal, hepatic, and cardiac function during therapy. Monitor patients taking medications known to affect blood pressure. Discontinue therapy if hypotension develops during the 5 days of administration. Renal Dose Adjustments Mild renal dysfunction (CrCl 60 to less than 90 mL/min): No adjustment is recommended. Moderate renal dysfunction (CrCl 30 to less than 60 mL/min): Reduce the starting dose by 50%. Severe renal dysfunction (CrCl less than 15 to less than 30 mL/min) and end-stage renal disease (CrCl less than 15 mL/min): Data not available Dose Adjustments Supportive Medications and Medications to Avoid: Consider prophylactic antiemetic medications as this drug is moderately emetogenic. Consider the use of prophylactic steroids to mitigate Systemic Inflammatory Response Syndrome (SIRS) or capillary leak syndrome (e.g., hypotension, tachycardia, tachypnea, pulmonary edema). Minimize exposure to drugs with known renal toxicity during the 5 days of therapy since the risk of renal toxicity may be increased. Consider avoiding the concomitant use of medications known to induce hepatic toxicity. Dose Modifications and Reinitiation of Therapy: HEMATOLOGIC TOXICITY: Administer subsequent cycles no sooner than 14 days from the starting day of the previous cycle and provided the patient ANC is 0.75 x 10(9)/L or greater. If a patient experiences Grade 4 neutropenia (ANC less than 0.5 x 10(9)/L) lasting 4 weeks or more, reduce the dose by 25% for the next cycle. NONHEMATOLOGIC TOXICITY: Withhold therapy if the patient develops a clinically significant infection, until the infection is controlled, then restart at the full dose. Withhold therapy for Grade 3 noninfectious nonhematologic toxicity (excluding transient elevations in serum transaminases and/or serum bilirubin and/or nausea/vomiting controlled by antiemetic therapy); reinstitute therapy at a 25% dose reduction with resolution or return to baseline. Discontinue therapy for Grade 4 noninfectious nonhematologic toxicity. Discontinue therapy if a patient shows early signs or symptoms of SIRS or capillary leak (e.g., hypotension, tachycardia, tachypnea, pulmonary edema) occur, and provide supportive measures. Discontinue therapy if Grade 3 or higher increases in creatinine or bilirubin are noted; reinstitute therapy at a 25% dose reduction, when the patient is stable and organ function has returned to baseline. If hyperuricemia is anticipated (tumor lysis), initiate measures to control uric acid. Side Effects The Most Common nausea vomiting stomach pain diarrhea constipation loss of appetite weight loss swelling of the inside of the mouth and nose painful white patches in the mouth headache anxiety depression irritability pain in the back, joints, arms, or legs drowsiness dry, itchy, or irritated skin flushing fast heartbeat fast breathing shortness of breath dizziness lightheadedness fainting decreased urination sore throat, cough, fever, chills, and other signs of infection pale skin excessive tiredness weakness confusion unusual bruising or bleeding nosebleed bleeding gums blood in urine small red or purple spots under the skin yellowing of the skin or eyes itching red, warm, swollen, tender skin uncontrollable shaking of a part of the body More Common Tumor lysis syndrome (TLS). Clofarabine quickly kills leukemia cells in the blood. The body may react to this. Signs include hyperkalemia, hyperuricemia, and hyperphosphatemia. TLS is very serious and can lead to death if it is not treated right away. Systemic inflammatory response syndrome (SIRS): symptoms include fast breathing, fast heartbeat, low blood pressure, and fluid in the lungs. Bone marrow problems (suppression). Clofarabine can stop the bone marrow from making enough red blood cells, white blood cells, and platelets. Serious side effects that can happen because of bone marrow suppression include severe infection (sepsis), bleeding, and anemia. Effects on pregnancy and breastfeeding. Girls and women should not become pregnant or breastfeed during treatment which may harm the baby. Dehydration and low blood pressure. Clofarabine can cause vomiting and diarrhea which may lead to low body fluid (dehydration). Signs and symptoms of dehydration include dizziness, lightheadedness, fainting spells, or decreased urination. Other side effects. The most common side effects are stomach problems (including vomiting, diarrhea, and nausea), and effects on blood cells (including low red blood cells count, low white blood cell count, low platelet count, fever, and infection). Clofarabine can also cause tachycardia and can affect the liver and kidneys. trouble breathing while lying down; diarrhea that is watery or bloody; little or no urination; pain, blisters, bleeding, or severe rash on the palms of your hands or the soles of your feet; low blood pressure–a light-headed feeling, like you might pass out; signs of a liver problem–upper stomach pain, sudden swelling in your mid-section, dark urine, jaundice (yellowing of the skin or eyes); signs of infection–fever, chills, tiredness, mouth and throat ulcers, skin sores, easy bruising, unusual bleeding, pale skin, cold hands and feet, shallow breathing; signs of bleeding inside the body–sudden numbness or weakness (especially on one side of the body), severe headache, problems with vision or speech, chest pain, coughing up blood, blood in your urine, bloody or tarry stools; or signs of tumor cell breakdown–tiredness, weakness, muscle cramps, nausea, vomiting, diarrhea, fast or slow heart rate, tingling in your hands and feet or around your mouth. Rare loss of appetite mouth sores, sore throat muscle aches nausea pain, redness or blistering of hands and feet rash sleepiness vomiting weakness changes in blood pressure diarrhea, nausea, and vomiting lasting more than 24 hours the feeling of being unwell fluid accumulating in the lungs (e.g., shortness of breath, rapid breathing, chest pain) muscle and joint pain inflammation in the digestive system (e.g., abdominal pain, fever, vomiting, diarrhea) rapid heartbeat shortness of breath signs of anemia (low red blood cells; e.g., dizziness, pale skin, unusual tiredness or weakness, shortness of breath) signs of bleeding (e.g., bloody nose, blood in urine, coughing blood, bleeding gums, cuts that don’t stop bleeding) signs of depression (e.g., poor concentration, changes in weight, changes in sleep, decreased interest in activities, thoughts of suicide) signs of liver problems (e.g., nausea, vomiting, diarrhea, loss of appetite, weight loss, yellowing of the skin or whites of the eyes, dark urine, pale stools) signs of fluid gathering around the heart (e.g., chest pain, shortness of breath when lying down, painful breathing, fainting, dizziness) signs of infection (symptoms may include fever or chills, severe diarrhea, shortness of breath, prolonged dizziness, headache, stiff neck, weight loss, or listlessness) signs of a serious allergic reaction (e.g., abdominal cramps, difficulty breathing, nausea and vomiting, or swelling of the face and throat) signs of severe bleeding (e.g., vomit resembling coffee grounds in texture and color, black tarry stools) Drug Interaction DRUG INTERACTION Abacavir Clofarabine may decrease the excretion rate of Abacavir which could result in a higher serum level. Abatacept The risk or severity of adverse effects can be increased when Clofarabine is combined with Abatacept. Abciximab The risk or severity of bleeding can be increased when Abciximab is combined with Clofarabine. Abemaciclib Abemaciclib may decrease the excretion rate of Clofarabine which could result in a higher serum level. Acebutolol The risk or severity of adverse effects can be increased when Clofarabine is combined with Acebutolol. Aceclofenac Aceclofenac may decrease the excretion rate of Clofarabine which could result in a higher serum level. Acemetacin Acemetacin may decrease the excretion rate of Clofarabine which could result in a higher serum level. Acenocoumarol The risk or severity of bleeding can be increased when Acenocoumarol is combined with Clofarabine. Acetaminophen Acetaminophen may decrease the excretion rate of Clofarabine which could result in a higher serum level. Acetazolamide Acetazolamide may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. Acetylsalicylic acid The excretion of Clofarabine can be decreased when combined with Acetylsalicylic acid. Aclidinium Clofarabine may decrease the excretion rate of Aclidinium which could result in a higher serum level. Acrivastine Clofarabine may decrease the excretion rate of Acrivastine which could result in a higher serum level. Acyclovir The excretion of Clofarabine can be decreased when combined with Acyclovir. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Clofarabine. Adefovir dipivoxil Adefovir dipivoxil may decrease the excretion rate of Clofarabine which could result in a higher serum level. Adenovirus type The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Clofarabine. Afatinib Afatinib may decrease the excretion rate of Clofarabine which could result in a higher serum level. Albutrepenonacog alfa Clofarabine may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level. Alclofenac Alclofenac may decrease the excretion rate of Clofarabine which could result in a higher serum level. Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Clofarabine. Alectinib Alectinib may decrease the excretion rate of Clofarabine which could result in a higher serum level. Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Clofarabine. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Clofarabine. Aliskiren The risk or severity of adverse effects can be increased when Clofarabine is combined with Aliskiren. Allogeneic processed The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Clofarabine. Allopurinol The risk or severity of adverse effects can be increased when Allopurinol is combined with Clofarabine. Almasilate Clofarabine may decrease the excretion rate of Almasilate which could result in a higher serum level. Almotriptan Clofarabine may decrease the excretion rate of Almotriptan which could result in a higher serum level. Alogliptin Clofarabine may decrease the excretion rate of Alogliptin which could result in a higher serum level. Alprazolam Alprazolam may decrease the excretion rate of Clofarabine which could result in a higher serum level. Alteplase The risk or severity of bleeding can be increased when Alteplase is combined with Clofarabine. Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Clofarabine. Amantadine The serum concentration of Clofarabine can be increased when it is combined with Amantadine. Ambrisentan Clofarabine may increase the hypotensive activities of Ambrisentan. Amifostine The risk or severity of adverse effects can be increased when Clofarabine is combined with Amifostine. Amikacin Clofarabine may decrease the excretion rate of Amikacin which could result in a higher serum level. Amiloride The serum concentration of Clofarabine can be increased when it is combined with Amiloride. Aminohippuric acid The serum concentration of Clofarabine can be increased when it is combined with Aminohippuric acid. Aminophenazone Aminophenazone may decrease the excretion rate of Clofarabine which could result in a higher serum level. Amiodarone The serum concentration of Clofarabine can be increased when it is combined with Amiodarone. Amitriptyline Amitriptyline may decrease the excretion rate of Clofarabine which could result in a higher serum level. Amlodipine The risk or severity of adverse effects can be increased when Amlodipine is combined with Clofarabine. Ammonium chloride Clofarabine may decrease the excretion rate of Ammonium chloride which could result in a higher serum level. Amobarbital Amobarbital may increase the hypotensive activities of Clofarabine. Amoxicillin Clofarabine may decrease the excretion rate of Amoxicillin which could result in a higher serum level. Amphetamine Amphetamine may decrease the excretion rate of Clofarabine which could result in a higher serum level. Amphotericin B The risk or severity of adverse effects can be increased when Clofarabine is combined with Amphotericin B. Ampicillin Ampicillin may decrease the excretion rate of Clofarabine which could result in a higher serum level. Amrinone Clofarabine may decrease the excretion rate of Amrinone which could result in a higher serum level. Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Clofarabine. Amyl Nitrite The risk or severity of adverse effects can be increased when Clofarabine is combined with Amyl Nitrite. Anagrelide The risk or severity of bleeding can be increased when Anagrelide is combined with Clofarabine. Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Clofarabine. Ancestim Clofarabine may decrease the excretion rate of Ancestim which could result in a higher serum level. Ancrod The risk or severity of bleeding can be increased when Ancrod is combined with Clofarabine. Anifrolumab The risk or severity of adverse effects can be increased when Clofarabine is combined with Anifrolumab. Anistreplase The risk or severity of bleeding can be increased when Anistreplase is combined with Clofarabine. Anthrax immune The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Clofarabine. Anthrax vaccine The risk or severity of infection can be increased when Anthrax vaccine is combined with Clofarabine. Antihemophilic Clofarabine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level. Antilymphocyte The risk or severity of adverse effects can be increased when Clofarabine is combined with Antilymphocyte immunoglobulin (horse). Antipyrine Antipyrine may decrease the excretion rate of Clofarabine which could result in a higher serum level. Antithrombin Alfa The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Clofarabine. Antithrombin III human Clofarabine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level. Antithymocyte The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Clofarabine. Antrafenine Antrafenine may decrease the excretion rate of Clofarabine which could result in a higher serum level. Apalutamide The serum concentration of Clofarabine can be increased when it is combined with Apalutamide. Apixaban The risk or severity of bleeding can be increased when Apixaban is combined with Clofarabine. Apomorphine The risk or severity of adverse effects can be increased when Clofarabine is combined with Apomorphine. Apremilast The risk or severity of adverse effects can be increased when Clofarabine is combined with Apremilast. Ardeparin The risk or severity of bleeding can be increased when Ardeparin is combined with Clofarabine. Arformoterol Clofarabine may decrease the excretion rate of Arformoterol which could result in a higher serum level. Argatroban The risk or severity of bleeding can be increased when Argatroban is combined with Clofarabine. Aripiprazole Aripiprazole may increase the hypotensive activities of Clofarabine. Aripiprazole lauroxil Aripiprazole lauroxil may increase the hypotensive activities of Clofarabine. Arsenic trioxide The risk or severity of adverse effects can be increased when Clofarabine is combined with Arsenic trioxide. Articaine The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Articaine. COVID-19 Vaccine The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Clofarabine. Ataluren The excretion of Clofarabine can be decreased when combined with Ataluren. Atazanavir Atazanavir may decrease the excretion rate of Clofarabine which could result in a higher serum level. Atenolol The risk or severity of adverse effects can be increased when Atenolol is combined with Clofarabine. Atomoxetine Atomoxetine may decrease the excretion rate of Clofarabine which could result in a higher serum level. Auranofin Clofarabine may decrease the excretion rate of Auranofin which could result in a higher serum level. Aurothioglucose Clofarabine may decrease the excretion rate of Aurothioglucose which could result in a higher serum level. Avanafil Avanafil may decrease the excretion rate of Clofarabine which could result in a higher serum level. Avatrombopag The excretion of Clofarabine can be decreased when combined with Avatrombopag. Azacitidine The risk or severity of adverse effects can be increased when Clofarabine is combined with Azacitidine. Azathioprine The risk or severity of adverse effects can be increased when Clofarabine is combined with Azathioprine. Azelaic acid Azelaic acid may decrease the excretion rate of Clofarabine which could result in a higher serum level. Azilsartan medoxomil The risk or severity of adverse effects can be increased when Clofarabine is combined with Azilsartan medoxomil. Aztreonam Aztreonam may decrease the excretion rate of Clofarabine which could result in a higher serum level. Bacillus The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Clofarabine. BCG-I live antigen The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Clofarabine. Bacillus The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Clofarabine. Bacitracin Bacitracin may decrease the excretion rate of Clofarabine which could result in a higher serum level. Baclofen Baclofen may decrease the excretion rate of Clofarabine which could result in a higher serum level. Balsalazide Balsalazide may decrease the excretion rate of Clofarabine which could result in a higher serum level. Baricitinib The risk or severity of adverse effects can be increased when Clofarabine is combined with Baricitinib. Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Clofarabine. Belatacept The risk or severity of adverse effects can be increased when Clofarabine is combined with Belatacept. Belimumab The risk or severity of adverse effects can be increased when Clofarabine is combined with Belimumab. Belinostat The risk or severity of adverse effects can be increased when Clofarabine is combined with Belinostat. Belumosudil The risk or severity of adverse effects can be increased when Clofarabine is combined with Belumosudil. Bemiparin The risk or severity of bleeding can be increased when Bemiparin is combined with Clofarabine. Benazepril The risk or severity of adverse effects can be increased when Benazepril is combined with Clofarabine. Bendamustine The risk or severity of adverse effects can be increased when Clofarabine is combined with Bendamustine. Bendroflumethiazide Bendroflumethiazide may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. Benorilate Benorilate may decrease the excretion rate of Clofarabine which could result in a higher serum level. Benoxaprofen Benoxaprofen may decrease the excretion rate of Clofarabine which could result in a higher serum level. Benserazide Clofarabine may decrease the excretion rate of Benserazide which could result in a higher serum level. Benzatropine Benzatropine may decrease the excretion rate of Clofarabine which could result in a higher serum level. Benznidazole Clofarabine may decrease the excretion rate of Benznidazole which could result in a higher serum level. Benzocaine The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Benzocaine. Benzoic acid The excretion of Clofarabine can be decreased when combined with Benzoic acid. Benzthiazide Benzthiazide may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. Benzydamine Benzydamine may decrease the excretion rate of Clofarabine which could result in a higher serum level. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Benzyl alcohol. Benzylpenicillin The excretion of Clofarabine can be decreased when combined with Benzylpenicillin. Bepotastine Clofarabine may decrease the excretion rate of Bepotastine which could result in a higher serum level. Bepridil The risk or severity of adverse effects can be increased when Clofarabine is combined with Bepridil. Betamethasone The risk or severity of adverse effects can be increased when Betamethasone is combined with Clofarabine. Betaxolol The risk or severity of adverse effects can be increased when Betaxolol is combined with Clofarabine. Bethanidine Clofarabine may increase the hypotensive activities of Bethanidine. Betrixaban The risk or severity of bleeding can be increased when Betrixaban is combined with Clofarabine. Bexarotene The risk or severity of adverse effects can be increased when Bexarotene is combined with Clofarabine. Bicisate Clofarabine may decrease the excretion rate of Bicisate which could result in a higher serum level. Bimekizumab The risk or severity of adverse effects can be increased when Clofarabine is combined with Bimekizumab. Bismuth subgallate Clofarabine may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level. Bisoprolol The risk or severity of adverse effects can be increased when Bisoprolol is combined with Clofarabine. Bisoxatin Clofarabine may decrease the excretion rate of Bisoxatin which could result in a higher serum level. Bivalirudin The risk or severity of bleeding can be increased when Bivalirudin is combined with Clofarabine. Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Clofarabine. Blinatumomab The risk or severity of adverse effects can be increased when Clofarabine is combined with Blinatumomab. Bordetella pertussis The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Clofarabine. Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Clofarabine. Bosentan Clofarabine may increase the hypotensive activities of Bosentan. Bosutinib The risk or severity of adverse effects can be increased when Clofarabine is combined with Bosutinib. Brentuximab vedotin The risk or severity of adverse effects can be increased when Clofarabine is combined with Brentuximab vedotin. Bretylium The risk or severity of adverse effects can be increased when Clofarabine is combined with Bretylium. Brigatinib Brigatinib may decrease the excretion rate of Clofarabine which could result in a higher serum level. Brivaracetam Clofarabine may decrease the excretion rate of Brivaracetam which could result in a higher serum level. Brodalumab The risk or severity of adverse effects can be increased when Clofarabine is combined with Brodalumab. Bromazepam Clofarabine may decrease the excretion rate of Bromazepam which could result in a higher serum level. Bromocriptine The risk or severity of adverse effects can be increased when Clofarabine is combined with Bromocriptine. Bromotheophylline Bromotheophylline may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. Budesonide The risk or severity of adverse effects can be increased when Clofarabine is combined with Budesonide. Bumadizone Bumadizone may decrease the excretion rate of Clofarabine which could result in a higher serum level. Bumetanide The excretion of Clofarabine can be decreased when combined with Bumetanide. Bupivacaine The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Bupivacaine. Buprenorphine Buprenorphine may decrease the excretion rate of Clofarabine which could result in a higher serum level. Bupropion The serum concentration of Clofarabine can be increased when it is combined with Bupropion. Buspirone Buspirone may decrease the excretion rate of Clofarabine which could result in a higher serum level. Busulfan The risk or severity of adverse effects can be increased when Clofarabine is combined with Busulfan. Butabarbital Butabarbital may increase the hypotensive activities of Clofarabine. Butacaine The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Butacaine. Butalbital Butalbital may increase the hypotensive activities of Clofarabine. Butamben The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Butamben. Cabazitaxel The risk or severity of adverse effects can be increased when Clofarabine is combined with Cabazitaxel. Cabotegravir The excretion of Clofarabine can be decreased when combined with Cabotegravir. Caffeine Caffeine may decrease the excretion rate of Clofarabine which could result in a higher serum level. Canagliflozin Canagliflozin may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. Canakinumab The risk or severity of adverse effects can be increased when Clofarabine is combined with Canakinumab. Candesartan The risk or severity of adverse effects can be increased when Clofarabine is combined with Candesartan cilexetil. Cangrelor The risk or severity of bleeding can be increased when Cangrelor is combined with Clofarabine. Cannabidiol Cannabidiol may decrease the excretion rate of Clofarabine which could result in a higher serum level. Canrenoic acid Canrenoic acid may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. Capecitabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Capecitabine. Caplacizumab The risk or severity of bleeding can be increased when Caplacizumab is combined with Clofarabine. Capmatinib The serum concentration of Clofarabine can be increased when it is combined with Capmatinib. Capreomycin Clofarabine may decrease the excretion rate of Capreomycin which could result in a higher serum level. Capsaicin The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Capsaicin. Captopril The risk or severity of adverse effects can be increased when Clofarabine is combined with Captopril. Carbamazepine The risk or severity of adverse effects can be increased when Carbamazepine is combined with Clofarabine. Carbetocin The risk or severity of adverse effects can be increased when Clofarabine is combined with Carbetocin. Carbidopa Carbidopa may decrease the excretion rate of Clofarabine which could result in a higher serum level. Carboplatin The risk or severity of adverse effects can be increased when Clofarabine is combined with Carboplatin. Carfilzomib The risk or severity of adverse effects can be increased when Clofarabine is combined with Carfilzomib. Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Clofarabine. Carprofen Carprofen may decrease the excretion rate of Clofarabine which could result in a higher serum level. Carvedilol The risk or severity of adverse effects can be increased when Clofarabine is combined with Carvedilol. Cefaclor The excretion of Clofarabine can be decreased when combined with Cefaclor. Cefadroxil The excretion of Clofarabine can be decreased when combined with Cefadroxil. Cefalotin The excretion of Clofarabine can be decreased when combined with Cefalotin. Cefamandole The excretion of Clofarabine can be decreased when combined with Cefamandole. Cefapirin Cefapirin may decrease the excretion rate of Clofarabine which could result in a higher serum level. Cefazolin The excretion of Clofarabine can be decreased when combined with Cefazolin. Cefdinir Cefdinir may decrease the excretion rate of Clofarabine which could result in a higher serum level. Cefditoren Cefditoren may decrease the excretion rate of Clofarabine which could result in a higher serum level. Cefepime Cefepime may decrease the excretion rate of Clofarabine which could result in a higher serum level. Cefmenoxime Cefmenoxime may decrease the excretion rate of Clofarabine which could result in a higher serum level. Cefmetazole Cefmetazole may decrease the excretion rate of Clofarabine which could result in a higher serum level. Cefonicid Cefonicid may decrease the excretion rate of Clofarabine which could result in a higher serum level. Cefoperazone The excretion of Clofarabine can be decreased when combined with Cefoperazone. Ceforanide Ceforanide may decrease the excretion rate of Clofarabine which could result in a higher serum level. Cefotaxime The excretion of Clofarabine can be decreased when combined with Cefotaxime. Cefotetan Cefotetan may decrease the excretion rate of Clofarabine which could result in a higher serum level. Cefotiam The excretion of Clofarabine can be decreased when combined with Cefotiam. You Might Also Read Pentoxifylline/Oxpentifylline; Uses, Dosage, Side Effects Cefoxitin Cefoxitin may decrease the excretion rate of Clofarabine which could result in a higher serum level. Cefpiramide Cefpiramide may decrease the excretion rate of Clofarabine which could result in a higher serum level. Cefpirome Cefpirome may decrease the excretion rate of Clofarabine which could result in a higher serum level. Cefpodoxime Cefpodoxime may decrease the excretion rate of Clofarabine which could result in a higher serum level. Cefprozil Cefprozil may decrease the excretion rate of Clofarabine which could result in a higher serum level. Cefradine Cefradine may decrease the excretion rate of Clofarabine which could result in a higher serum level. Ceftaroline fosamil Ceftaroline fosamil may decrease the excretion rate of Clofarabine which could result in a higher serum level. Ceftazidime Ceftazidime may decrease the excretion rate of Clofarabine which could result in a higher serum level. Ceftibuten The excretion of Clofarabine can be decreased when combined with Ceftibuten. Ceftizoxime The excretion of Clofarabine can be decreased when combined with Ceftizoxime. Ceftobiprole Ceftobiprole may decrease the excretion rate of Clofarabine which could result in a higher serum level. Ceftolozane Clofarabine may decrease the excretion rate of Ceftolozane which could result in a higher serum level. Ceftriaxone The excretion of Clofarabine can be decreased when combined with Ceftriaxone. Cefuroxime Cefuroxime may decrease the excretion rate of Clofarabine which could result in a higher serum level. Celecoxib Celecoxib may decrease the excretion rate of Clofarabine which could result in a higher serum level. Celiprolol Clofarabine may increase the hypotensive activities of Celiprolol. Cephalexin The excretion of Clofarabine can be decreased when combined with Cephalexin. Cephaloglycin Cephaloglycin may decrease the excretion rate of Clofarabine which could result in a higher serum level. Certolizumab pegol The risk or severity of adverse effects can be increased when Clofarabine is combined with Certolizumab pegol. Cetirizine Cetirizine may decrease the excretion rate of Clofarabine which could result in a higher serum level. Cevimeline Cevimeline may decrease the excretion rate of Clofarabine which could result in a higher serum level. Chloral hydrate Clofarabine may decrease the excretion rate of Chloral hydrate which could result in a higher serum level. Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Clofarabine. Chloramphenicol The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Clofarabine. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Chloroprocaine. Chloroquine Chloroquine may decrease the excretion rate of Clofarabine which could result in a higher serum level. Chlorothiazide Chlorothiazide may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. Chloroxylenol Clofarabine may decrease the excretion rate of Chloroxylenol which could result in a higher serum level. Chlorpheniramine The serum concentration of Clofarabine can be increased when it is combined with Chlorpheniramine. Chlorpromazine The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Clofarabine. Chlorpropamide Clofarabine may decrease the excretion rate of Chlorpropamide which could result in a higher serum level. Chlorthalidone Chlorthalidone may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. Chlorzoxazone Chlorzoxazone may decrease the excretion rate of Clofarabine which could result in a higher serum level. Cholesterol Cholesterol may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. Cholic Acid The excretion of Clofarabine can be decreased when combined with Cholic Acid. Choline The serum concentration of Clofarabine can be increased when it is combined with Choline. Choline C 11 Clofarabine may decrease the excretion rate of Choline C 11 which could result in a higher serum level. Choline magnesium Choline magnesium trisalicylate may decrease the excretion rate of Clofarabine which could result in a higher serum level. Choline salicylate The serum concentration of Clofarabine can be increased when it is combined with Choline salicylate. Chondroitin sulfate Clofarabine may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level. Chromic chloride Clofarabine may decrease the excretion rate of Chromic chloride which could result in a higher serum level. Chromic nitrate Clofarabine may decrease the excretion rate of Chromic nitrate which could result in a higher serum level. Chromium Clofarabine may decrease the excretion rate of Chromium which could result in a higher serum level. Chromium gluconate Clofarabine may decrease the excretion rate of Chromium gluconate which could result in a higher serum level. Chromium nicotinate Clofarabine may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level. Chromous sulfate Clofarabine may decrease the excretion rate of Chromous sulfate which could result in a higher serum level. Ciclesonide The risk or severity of adverse effects can be increased when Clofarabine is combined with Ciclesonide. Cidofovir Cidofovir may decrease the excretion rate of Clofarabine which could result in a higher serum level. Cilastatin The excretion of Clofarabine can be decreased when combined with Cilastatin. Cilazapril The risk or severity of adverse effects can be increased when Clofarabine is combined with Cilazapril. Cilostazol The risk or severity of bleeding can be increased when Cilostazol is combined with Clofarabine. Cimetidine The serum concentration of Clofarabine can be increased when it is combined with Cimetidine. Cinchocaine The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Cinchocaine. Ciprofloxacin Ciprofloxacin may decrease the excretion rate of Clofarabine which could result in a higher serum level. Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Clofarabine. Cladribine The risk or severity of adverse effects can be increased when Cladribine is combined with Clofarabine. Clevidipine The risk or severity of adverse effects can be increased when Clofarabine is combined with Clevidipine. Clobazam Clobazam may decrease the excretion rate of Clofarabine which could result in a higher serum level. Clobetasol propionate The risk or severity of adverse effects can be increased when Clofarabine is combined with Clobetasol propionate. Clofazimine Clofazimine may decrease the excretion rate of Clofarabine which could result in a higher serum level. Clomipramine The risk or severity of adverse effects can be increased when Clofarabine is combined with Clomipramine. Clonazepam Clofarabine may decrease the excretion rate of Clonazepam which could result in a higher serum level. Clonidine The risk or severity of adverse effects can be increased when Clonidine is combined with Clofarabine. Clopidogrel The serum concentration of Clofarabine can be increased when it is combined with Clopidogrel. Clorazepic acid Clorazepic acid may decrease the excretion rate of Clofarabine which could result in a higher serum level. Clostridium tetani The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Clofarabine. Clove oil Clofarabine may decrease the excretion rate of Clove oil which could result in a higher serum level. Clozapine The risk or severity of neutropenia can be increased when Clofarabine is combined with Clozapine. Cobicistat Cobicistat may decrease the excretion rate of Clofarabine which could result in a higher serum level. Cocaine The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Cocaine. Colchicine Clofarabine may decrease the excretion rate of Colchicine which could result in a higher serum level. Colistimethate Colistimethate may decrease the excretion rate of Clofarabine which could result in a higher serum level. Colistin Clofarabine may decrease the excretion rate of Colistin which could result in a higher serum level. Conivaptan Conivaptan may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. Conjugated estrogens The excretion of Clofarabine can be decreased when combined with Conjugated estrogens. Corifollitropin alfa Clofarabine may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level. Corticotropin The risk or severity of adverse effects can be increased when Clofarabine is combined with Corticotropin. Cortisone acetate The risk or severity of adverse effects can be increased when Clofarabine is combined with Cortisone acetate. Corynebacterium The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Clofarabine. Crizotinib The serum concentration of Clofarabine can be increased when it is combined with Crizotinib. Cryptenamine Clofarabine may increase the hypotensive activities of Cryptenamine. Cyanocobalamin The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Clofarabine. Cyclopenthiazide Cyclopenthiazide may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. Cyclophosphamide The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Clofarabine. Cyclosporine Clofarabine may increase the immunosuppressive activities of Cyclosporine. Cyclothiazide Cyclothiazide may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. Cytarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Cytarabine. Dabigatran The risk or severity of bleeding can be increased when Dabigatran is combined with Clofarabine. Dabigatran etexilate Clofarabine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level. Dabrafenib The serum concentration of Clofarabine can be increased when it is combined with Dabrafenib. Dacarbazine The risk or severity of adverse effects can be increased when Clofarabine is combined with Dacarbazine. Daclatasvir Daclatasvir may decrease the excretion rate of Clofarabine which could result in a higher serum level. Dacomitinib Dacomitinib may decrease the excretion rate of Clofarabine which could result in a higher serum level. Dactinomycin The risk or severity of adverse effects can be increased when Clofarabine is combined with Dactinomycin. Dalfampridine Clofarabine may decrease the excretion rate of Dalfampridine which could result in a higher serum level. Dalteparin The risk or severity of bleeding can be increased when Dalteparin is combined with Clofarabine. Danaparoid The risk or severity of bleeding can be increased when Danaparoid is combined with Clofarabine. Dapagliflozin Dapagliflozin may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. Daptomycin Daptomycin may decrease the excretion rate of Clofarabine which could result in a higher serum level. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Clofarabine. Darolutamide Darolutamide may decrease the excretion rate of Clofarabine which could result in a higher serum level. Dasabuvir Dasabuvir may decrease the excretion rate of Clofarabine which could result in a higher serum level. Dasatinib The risk or severity of adverse effects can be increased when Clofarabine is combined with Dasatinib. Dasiglucagon Clofarabine may increase the hypotensive activities of Dasiglucagon. Daunorubicin The risk or severity of adverse effects can be increased when Clofarabine is combined with Daunorubicin. Debrisoquine Clofarabine may increase the hypotensive activities of Debrisoquine. Decitabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Decitabine. Deferiprone Clofarabine may decrease the excretion rate of Deferiprone which could result in a higher serum level. Defibrotide The risk or severity of bleeding can be increased when Defibrotide is combined with Clofarabine. Deflazacort The risk or severity of adverse effects can be increased when Clofarabine is combined with Deflazacort. Delafloxacin Clofarabine may decrease the excretion rate of Delafloxacin which could result in a higher serum level. Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Clofarabine. Deserpidine Clofarabine may increase the hypotensive activities of Deserpidine. Desflurane The risk or severity of adverse effects can be increased when Clofarabine is combined with Desflurane. Desipramine The serum concentration of Clofarabine can be increased when it is combined with Desipramine. Desirudin The risk or severity of bleeding can be increased when Desirudin is combined with Clofarabine. Desmopressin Desmopressin may decrease the excretion rate of Clofarabine which could result in a higher serum level. Desoximetasone The risk or severity of adverse effects can be increased when Desoximetasone is combined with Clofarabine. Desvenlafaxine Clofarabine may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level. Deucravacitinib The risk or severity of adverse effects can be increased when Clofarabine is combined with Deucravacitinib. Deutetrabenazine Clofarabine may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level. Dexamethasone The risk or severity of adverse effects can be increased when Clofarabine is combined with Dexamethasone. Dexamethasone acetate Dexamethasone acetate may decrease the excretion rate of Clofarabine which could result in a higher serum level. Dexchlorpheniramine The serum concentration of Clofarabine can be increased when it is combined with Dexchlorpheniramine maleate. Dexibuprofen Dexibuprofen may decrease the excretion rate of Clofarabine which could result in a higher serum level. Dexketoprofen Dexketoprofen may decrease the excretion rate of Clofarabine which could result in a higher serum level. Dexmedetomidine The risk or severity of adverse effects can be increased when Clofarabine is combined with Dexmedetomidine. Dexpanthenol Clofarabine may decrease the excretion rate of Dexpanthenol which could result in a higher serum level. Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Clofarabine. Dextran Clofarabine may decrease the excretion rate of Dextran which could result in a higher serum level. Diatrizoate Diatrizoate may decrease the excretion rate of Clofarabine which could result in a higher serum level. Diazepam Clofarabine may decrease the excretion rate of Diazepam which could result in a higher serum level. Diazoxide The risk or severity of adverse effects can be increased when Clofarabine is combined with Diazoxide. Dichlorobenzyl alcohol Clofarabine may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level. Diclofenac The excretion of Clofarabine can be decreased when combined with Diclofenac. Diclofenamide Diclofenamide may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. Dicoumarol The risk or severity of bleeding can be increased when Dicoumarol is combined with Clofarabine. Dicyclomine Clofarabine may decrease the excretion rate of Dicyclomine which could result in a higher serum level. Didanosine Clofarabine may decrease the excretion rate of Didanosine which could result in a higher serum level. Dienogest Clofarabine may decrease the excretion rate of Dienogest which could result in a higher serum level. Diethylstilbestrol Diethylstilbestrol may decrease the excretion rate of Clofarabine which could result in a higher serum level. Diflunisal Diflunisal may decrease the excretion rate of Clofarabine which could result in a higher serum level. Difluocortolone The risk or severity of adverse effects can be increased when Clofarabine is combined with Difluocortolone. Digoxin Clofarabine may decrease the excretion rate of Digoxin which could result in a higher serum level. Dihydralazine Clofarabine may increase the hypotensive activities of Dihydralazine. Dihydrostreptomycin Dihydrostreptomycin may decrease the excretion rate of Clofarabine which could result in a higher serum level. Diltiazem The risk or severity of adverse effects can be increased when Diltiazem is combined with Clofarabine. Dimercaprol Clofarabine may decrease the excretion rate of Dimercaprol which could result in a higher serum level. Dimethyl fumarate The risk or severity of adverse effects can be increased when Clofarabine is combined with Dimethyl fumarate. Dimethyl sulfoxide Clofarabine may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level. Dinoprostone The serum concentration of Clofarabine can be increased when it is combined with Dinoprostone. Dinutuximab The risk or severity of adverse effects can be increased when Clofarabine is combined with Dinutuximab. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Diphenhydramine. Dipyridamole The risk or severity of adverse effects can be increased when Clofarabine is combined with Dipyridamole. Diroximel fumarate The risk or severity of adverse effects can be increased when Clofarabine is combined with Diroximel fumarate. Disopyramide The serum concentration of Clofarabine can be increased when it is combined with Disopyramide. DL-Methylephedrine Clofarabine may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level. Dobutamine Clofarabine may decrease the excretion rate of Dobutamine which could result in a higher serum level. Docetaxel The risk or severity of adverse effects can be increased when Clofarabine is combined with Docetaxel. Dolutegravir The serum concentration of Clofarabine can be increased when it is combined with Dolutegravir. Dopamine The serum concentration of Clofarabine can be increased when it is combined with Dopamine. Doripenem Clofarabine may decrease the excretion rate of Doripenem which could result in a higher serum level. Doxacurium Clofarabine may decrease the excretion rate of Doxacurium which could result in a higher serum level. Doxazosin The risk or severity of adverse effects can be increased when Doxazosin is combined with Clofarabine. Doxepin Clofarabine may decrease the excretion rate of Doxepin which could result in a higher serum level. Doxorubicin The risk or severity of adverse effects can be increased when Clofarabine is combined with Doxorubicin. Doxycycline Doxycycline may decrease the excretion rate of Clofarabine which could result in a higher serum level. Dronedarone The serum concentration of Clofarabine can be increased when it is combined with Dronedarone. Drospirenone Drospirenone may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. Drotrecogin alfa The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Clofarabine. Droxidopa Clofarabine may decrease the excretion rate of Droxidopa which could result in a higher serum level. Duloxetine The risk or severity of orthostatic hypotension and syncope can be increased when Clofarabine is combined with Duloxetine. Dyclonine The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Dyclonine. Dyphylline Clofarabine may decrease the excretion rate of Dyphylline which could result in a higher serum level. Ebola Zaire vaccine The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Clofarabine. Eculizumab The risk or severity of adverse effects can be increased when Clofarabine is combined with Eculizumab. Edetic acid The risk or severity of bleeding can be increased when Edetic acid is combined with Clofarabine. Edoxaban Clofarabine may decrease the excretion rate of Edoxaban which could result in a higher serum level. Edrophonium Clofarabine may decrease the excretion rate of Edrophonium which could result in a higher serum level. Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Clofarabine. Elbasvir Elbasvir may decrease the excretion rate of Clofarabine which could result in a higher serum level. Eltrombopag Eltrombopag may decrease the excretion rate of Clofarabine which could result in a higher serum level. Emapalumab The risk or severity of adverse effects can be increased when Clofarabine is combined with Emapalumab. Empagliflozin The risk or severity of adverse effects can be increased when Clofarabine is combined with Empagliflozin. Enalapril The excretion of Clofarabine can be decreased when combined with Enalapril. Enalaprilat The risk or severity of adverse effects can be increased when Clofarabine is combined with Enalaprilat. Enasidenib The serum concentration of Clofarabine can be increased when it is combined with Enasidenib. Enoxaparin The risk or severity of bleeding can be increased when Enoxaparin is combined with Clofarabine. Enzalutamide Clofarabine may decrease the excretion rate of Enzalutamide which could result in a higher serum level. Epinephrine The serum concentration of Clofarabine can be increased when it is combined with Epinephrine. Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Clofarabine. Eplerenone Eplerenone may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. Epoprostenol The risk or severity of adverse effects can be increased when Clofarabine is combined with Epoprostenol. Eprosartan The risk or severity of adverse effects can be increased when Clofarabine is combined with Eprosartan. Eptifibatide The risk or severity of bleeding can be increased when Eptifibatide is combined with Clofarabine. Erdafitinib The serum concentration of Clofarabine can be increased when it is combined with Erdafitinib. Eribulin The risk or severity of adverse effects can be increased when Clofarabine is combined with Eribulin. Erlotinib Erlotinib may decrease the excretion rate of Clofarabine which could result in a higher serum level. Ertapenem Ertapenem may decrease the excretion rate of Clofarabine which could result in a higher serum level. Ertugliflozin Ertugliflozin may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Clofarabine. Esmolol The risk or severity of adverse effects can be increased when Esmolol is combined with Clofarabine. Esomeprazole The excretion of Clofarabine can be decreased when combined with Esomeprazole. Estazolam Clofarabine may decrease the excretion rate of Estazolam which could result in a higher serum level. Estradiol The serum concentration of Clofarabine can be increased when it is combined with Estradiol. Estradiol acetate The serum concentration of Clofarabine can be increased when it is combined with Estradiol acetate. Estradiol benzoate The serum concentration of Clofarabine can be increased when it is combined with Estradiol benzoate. Estradiol cypionate The serum concentration of Clofarabine can be increased when it is combined with Estradiol cypionate. Estradiol dienanthate The serum concentration of Clofarabine can be increased when it is combined with Estradiol dienanthate. Estradiol valerate The serum concentration of Clofarabine can be increased when it is combined with Estradiol valerate. Estramustine The risk or severity of adverse effects can be increased when Clofarabine is combined with Estramustine. Estrone sulfate Clofarabine may decrease the excretion rate of Estrone sulfate which could result in a higher serum level. Eszopiclone Eszopiclone may decrease the excretion rate of Clofarabine which could result in a higher serum level. Etacrynic acid Etacrynic acid may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. Etafedrine Clofarabine may decrease the excretion rate of Etafedrine which could result in a higher serum level. Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Clofarabine. Ethambutol Ethambutol may decrease the excretion rate of Clofarabine which could result in a higher serum level. Ethanol Ethanol may increase the hypotensive activities of Clofarabine. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Etidocaine. Etodolac Etodolac may decrease the excretion rate of Clofarabine which could result in a higher serum level. Etomidate Etomidate may decrease the excretion rate of Clofarabine which could result in a higher serum level. Etonogestrel Etonogestrel may decrease the excretion rate of Clofarabine which could result in a higher serum level. Etoposide The risk or severity of adverse effects can be increased when Clofarabine is combined with Etoposide. Etoricoxib Etoricoxib may decrease the excretion rate of Clofarabine which could result in a higher serum level. Eucalyptus oil Clofarabine may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level. Everolimus The risk or severity of adverse effects can be increased when Clofarabine is combined with Everolimus. Ezogabine Clofarabine may decrease the excretion rate of Ezogabine which could result in a higher serum level. Famotidine The serum concentration of Clofarabine can be increased when it is combined with Famotidine. Famtozinameran The therapeutic efficacy of Famtozinameran can be decreased when used in combination with Clofarabine. Favipiravir The excretion of Clofarabine can be decreased when combined with Favipiravir. Febuxostat The excretion of Clofarabine can be decreased when combined with Febuxostat. Fedratinib Fedratinib may decrease the excretion rate of Clofarabine which could result in a higher serum level. Felodipine The risk or severity of adverse effects can be increased when Clofarabine is combined with Felodipine. Fenbufen Fenbufen may decrease the excretion rate of Clofarabine which could result in a higher serum level. Fenofibrate Clofarabine may decrease the excretion rate of Fenofibrate which could result in a higher serum level. Fenofibric acid Clofarabine may decrease the excretion rate of Fenofibric acid which could result in a higher serum level. Fenoldopam The risk or severity of adverse effects can be increased when Clofarabine is combined with Fenoldopam. Fenoprofen Fenoprofen may decrease the excretion rate of Clofarabine which could result in a higher serum level. Fentanyl Clofarabine may decrease the excretion rate of Fentanyl which could result in a higher serum level. Fesoterodine Clofarabine may decrease the excretion rate of Fesoterodine which could result in a higher serum level. Fexinidazole The serum concentration of Clofarabine can be increased when it is combined with Fexinidazole. Filgotinib The risk or severity of adverse effects can be increased when Clofarabine is combined with Filgotinib. Finerenone Finerenone may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. Fingolimod Clofarabine may increase the immunosuppressive activities of Fingolimod. Flavoxate Clofarabine may decrease the excretion rate of Flavoxate which could result in a higher serum level. Floctafenine Floctafenine may decrease the excretion rate of Clofarabine which could result in a higher serum level. Florbetaben (18F) Clofarabine may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level. Florbetapir (18F) Clofarabine may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level. Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Clofarabine. Fluconazole Fluconazole may decrease the excretion rate of Clofarabine which could result in a higher serum level. Flucytosine The risk or severity of adverse effects can be increased when Clofarabine is combined with Flucytosine. Fludarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Fludarabine. Fludeoxyglucose (18F) Clofarabine may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level. Fludrocortisone The risk or severity of adverse effects can be increased when Clofarabine is combined with Fludrocortisone. Fluindione The risk or severity of bleeding can be increased when Fluindione is combined with Clofarabine. Flumazenil Clofarabine may decrease the excretion rate of Flumazenil which could result in a higher serum level. Flunisolide The risk or severity of adverse effects can be increased when Flunisolide is combined with Clofarabine. Fluocinolone acetonide The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Clofarabine. Fluocinonide The risk or severity of adverse effects can be increased when Clofarabine is combined with Fluocinonide. Fluocortolone The risk or severity of adverse effects can be increased when Clofarabine is combined with Fluocortolone. Fluorometholone The risk or severity of adverse effects can be increased when Fluorometholone is combined with Clofarabine. Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Clofarabine. Flupentixol The risk or severity of myelosuppression can be increased when Flupentixol is combined with Clofarabine. Fluprednisolone The risk or severity of adverse effects can be increased when Clofarabine is combined with Fluprednisolone. Flurazepam The serum concentration of Clofarabine can be increased when it is combined with Flurazepam. Flurbiprofen Flurbiprofen may decrease the excretion rate of Clofarabine which could result in a higher serum level. Flutamide Flutamide may decrease the excretion rate of Clofarabine which could result in a higher serum level. Fluticasone The risk or severity of adverse effects can be increased when Clofarabine is combined with Fluticasone. Fluticasone furoate The risk or severity of adverse effects can be increased when Clofarabine is combined with Fluticasone furoate. Fluticasone propionate The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Clofarabine. Fluvoxamine Fluvoxamine may decrease the excretion rate of Clofarabine which could result in a higher serum level. Folic acid Folic acid may decrease the excretion rate of Clofarabine which could result in a higher serum level. Fomepizole Clofarabine may decrease the excretion rate of Fomepizole which could result in a higher serum level. Fondaparinux Fondaparinux may decrease the excretion rate of Clofarabine which could result in a higher serum level. Formestane Clofarabine may decrease the excretion rate of Formestane which could result in a higher serum level. Foscarnet Foscarnet may decrease the excretion rate of Clofarabine which could result in a higher serum level. Fosfomycin Clofarabine may decrease the excretion rate of Fosfomycin which could result in a higher serum level. Fosinopril The risk or severity of adverse effects can be increased when Fosinopril is combined with Clofarabine. Fostamatinib Fostamatinib may decrease the excretion rate of Clofarabine which could result in a higher serum level. Fostemsavir Fostemsavir may decrease the excretion rate of Clofarabine which could result in a higher serum level. Framycetin Framycetin may decrease the excretion rate of Clofarabine which could result in a higher serum level. Furosemide The excretion of Clofarabine can be decreased when combined with Furosemide. Fusidic acid Fusidic acid may decrease the excretion rate of Clofarabine which could result in a higher serum level. Gabapentin enacarbil Clofarabine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level. Gadobenic acid Clofarabine may decrease the excretion rate of Gadobenic acid which could result in a higher serum level. Gadodiamide Gadodiamide may decrease the excretion rate of Clofarabine which could result in a higher serum level. Gadofosveset trisodium Clofarabine may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level. Gadopentetic acid Clofarabine may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level. Gadoteric acid Clofarabine may decrease the excretion rate of Gadoteric acid which could result in a higher serum level. Gadoteridol Gadoteridol may decrease the excretion rate of Clofarabine which could result in a higher serum level. Gallium nitrate The risk or severity of adverse effects can be increased when Clofarabine is combined with Gallium nitrate. Ganciclovir The excretion of Clofarabine can be decreased when combined with Ganciclovir. Gefitinib Gefitinib may decrease the excretion rate of Clofarabine which could result in a higher serum level. Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Clofarabine. Gemfibrozil The excretion of Clofarabine can be decreased when combined with Gemfibrozil. Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Clofarabine. Gentamicin Clofarabine may decrease the excretion rate of Gentamicin which could result in a higher serum level. Gilteritinib Gilteritinib may decrease the excretion rate of Clofarabine which could result in a higher serum level. Gimeracil Clofarabine may decrease the excretion rate of Gimeracil which could result in a higher serum level. You Might Also Read Gefitinib - Uses, Dosage, Side Effects, Interaction Glipizide Clofarabine may decrease the excretion rate of Glipizide which could result in a higher serum level. Glycerol Clofarabine may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level. Golimumab The risk or severity of adverse effects can be increased when Clofarabine is combined with Golimumab. Golodirsen Clofarabine may decrease the excretion rate of Golodirsen which could result in a higher serum level. Goserelin Goserelin may decrease the excretion rate of Clofarabine which could result in a higher serum level. Grazoprevir Grazoprevir may decrease the excretion rate of Clofarabine which could result in a higher serum level. Grepafloxacin The serum concentration of Clofarabine can be increased when it is combined with Grepafloxacin. Guanabenz Clofarabine may increase the hypotensive activities of Guanabenz. Guanadrel Clofarabine may increase the hypotensive activities of Guanadrel. Guanethidine Clofarabine may decrease the excretion rate of Guanethidine which could result in a higher serum level. Guanfacine The risk or severity of adverse effects can be increased when Clofarabine is combined with Guanfacine. Guanidine The serum concentration of Clofarabine can be increased when it is combined with Guanidine. Guanoxan Clofarabine may increase the hypotensive activities of Guanoxan. Guselkumab The risk or severity of adverse effects can be increased when Clofarabine is combined with Guselkumab. Haemophilus The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Clofarabine. Haloperidol Haloperidol may decrease the excretion rate of Clofarabine which could result in a higher serum level. Halothane The risk or severity of adverse effects can be increased when Clofarabine is combined with Halothane. Heparin The risk or severity of bleeding can be increased when Heparin is combined with Clofarabine. Hepatitis A Vaccine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Clofarabine. Hepatitis B Vaccine The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Clofarabine. Histamine The serum concentration of Clofarabine can be increased when it is combined with Histamine. Human adenovirus The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Clofarabine. Hydralazine The risk or severity of adverse effects can be increased when Clofarabine is combined with Hydralazine. Hydrochlorothiazide Hydrochlorothiazide may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. Hydrocortisone The risk or severity of adverse effects can be increased when Clofarabine is combined with Hydrocortisone acetate. Hydrocortisone The risk or severity of adverse effects can be increased when Clofarabine is combined with Hydrocortisone butyrate. Hydrocortisone The risk or severity of adverse effects can be increased when Clofarabine is combined with Hydrocortisone succinate. Hydroflumethiazide Hydroflumethiazide may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. Hydromorphone Hydromorphone may decrease the excretion rate of Clofarabine which could result in a higher serum level. Hydroxocobalamin Hydroxocobalamin may decrease the excretion rate of Clofarabine which could result in a higher serum level. Hydroxychloroquine The risk or severity of adverse effects can be increased when Clofarabine is combined with Hydroxychloroquine. Hydroxyethyl Starch Clofarabine may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level. Hydroxyurea The risk or severity of adverse effects can be increased when Clofarabine is combined with Hydroxyurea. Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Clofarabine. Ibrutinib The risk or severity of adverse effects can be increased when Clofarabine is combined with Ibrutinib. Ibuprofen The excretion of Clofarabine can be decreased when combined with Ibuprofen. Ibutilide Ibutilide may decrease the excretion rate of Clofarabine which could result in a higher serum level. Icatibant Clofarabine may decrease the excretion rate of Icatibant which could result in a higher serum level. Icosapent Icosapent may decrease the excretion rate of Clofarabine which could result in a higher serum level. Icosapent ethyl The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Clofarabine. Idarubicin The risk or severity of adverse effects can be increased when Clofarabine is combined with Idarubicin. Idarucizumab Clofarabine may decrease the excretion rate of Idarucizumab which could result in a higher serum level. Idebenone Clofarabine may decrease the excretion rate of Idebenone which could result in a higher serum level. Idelalisib The risk or severity of adverse effects can be increased when Clofarabine is combined with Idelalisib. Ifosfamide The risk or severity of adverse effects can be increased when Clofarabine is combined with Ifosfamide. Iloprost The risk or severity of adverse effects can be increased when Clofarabine is combined with Iloprost. Imatinib The risk or severity of adverse effects can be increased when Imatinib is combined with Clofarabine. Imipramine The serum concentration of Clofarabine can be increased when it is combined with Imipramine. Indapamide Indapamide may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. Indigotindisulfonic Clofarabine may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level. Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Clofarabine. Indoramin The risk or severity of adverse effects can be increased when Clofarabine is combined with Indoramin. Inebilizumab The risk or severity of infection can be increased when Clofarabine is combined with Inebilizumab. Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Clofarabine. Kanamycin Clofarabine may decrease the excretion rate of Kanamycin which could result in a higher serum level. Ketamine Clofarabine may decrease the excretion rate of Ketamine which could result in a higher serum level. Ketazolam Clofarabine may decrease the excretion rate of Ketazolam which could result in a higher serum level. Ketoprofen The excretion of Clofarabine can be decreased when combined with Ketoprofen. Ketorolac Ketorolac may decrease the excretion rate of Clofarabine which could result in a higher serum level. Labetalol The risk or severity of adverse effects can be increased when Labetalol is combined with Clofarabine. Lacidipine Clofarabine may increase the hypotensive activities of Lacidipine. Lamivudine Clofarabine may decrease the excretion rate of Lamivudine which could result in a higher serum level. Lamotrigine The serum concentration of Clofarabine can be increased when it is combined with Lamotrigine. Lansoprazole The excretion of Clofarabine can be decreased when combined with Lansoprazole. Lasmiditan The serum concentration of Clofarabine can be increased when it is combined with Lasmiditan. Latamoxef Latamoxef may decrease the excretion rate of Clofarabine which could result in a higher serum level. Ledipasvir Ledipasvir may decrease the excretion rate of Clofarabine which could result in a higher serum level. Leflunomide The risk or severity of adverse effects can be increased when Clofarabine is combined with Leflunomide. Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Clofarabine. Lenvatinib The serum concentration of Clofarabine can be increased when it is combined with Lenvatinib. Lepirudin The risk or severity of bleeding can be increased when Lepirudin is combined with Clofarabine. Lercanidipine The risk or severity of adverse effects can be increased when Lercanidipine is combined with Clofarabine. Lesinurad Clofarabine may decrease the excretion rate of Lesinurad which could result in a higher serum level. Letermovir The excretion of Clofarabine can be decreased when combined with Letermovir. Leucovorin The excretion of Clofarabine can be decreased when combined with Leucovorin. Leuprolide Leuprolide may decrease the excretion rate of Clofarabine which could result in a higher serum level. Levamlodipine Clofarabine may increase the hypotensive activities of Levamlodipine. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Levobupivacaine. Levocarnitine Levocarnitine may decrease the excretion rate of Clofarabine which could result in a higher serum level. Levocetirizine Clofarabine may decrease the excretion rate of Levocetirizine which could result in a higher serum level. Levodopa The risk or severity of hypotension and orthostatic hypotension can be increased when Clofarabine is combined with Levodopa. Levofloxacin Clofarabine may decrease the excretion rate of Levofloxacin which could result in a higher serum level. Levoketoconazole The serum concentration of Clofarabine can be increased when it is combined with Levoketoconazole. Levomilnacipran Clofarabine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level. Levosalbutamol Clofarabine may decrease the excretion rate of Levosalbutamol which could result in a higher serum level. Levosimendan The risk or severity of adverse effects can be increased when Clofarabine is combined with Levosimendan. Lidocaine The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Lidocaine. Linagliptin The serum concentration of Clofarabine can be increased when it is combined with Linagliptin. Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Clofarabine. Liothyronine The excretion of Clofarabine can be decreased when combined with Liothyronine. Liotrix The excretion of Clofarabine can be decreased when combined with Liotrix. Lipegfilgrastim Clofarabine may increase the myelosuppressive activities of Lipegfilgrastim. Lisinopril The risk or severity of adverse effects can be increased when Clofarabine is combined with Lisinopril. Lithium carbonate Clofarabine may decrease the excretion rate of Lithium carbonate which could result in a higher serum level. Lithium citrate Lithium citrate may decrease the excretion rate of Clofarabine which could result in a higher serum level. Lixisenatide Clofarabine may decrease the excretion rate of Lixisenatide which could result in a higher serum level. Lofexidine The risk or severity of adverse effects can be increased when Clofarabine is combined with Lofexidine. Lomustine The risk or severity of adverse effects can be increased when Clofarabine is combined with Lomustine. Lopinavir The serum concentration of Clofarabine can be increased when it is combined with Lopinavir. Loracarbef Loracarbef may decrease the excretion rate of Clofarabine which could result in a higher serum level. Lorazepam Lorazepam may decrease the excretion rate of Clofarabine which could result in a higher serum level. Lorcaserin Clofarabine may decrease the excretion rate of Lorcaserin which could result in a higher serum level. Lornoxicam Lornoxicam may decrease the excretion rate of Clofarabine which could result in a higher serum level. Lorpiprazole Clofarabine may decrease the excretion rate of Lorpiprazole which could result in a higher serum level. Losartan The risk or severity of adverse effects can be increased when Clofarabine is combined with Losartan. Loxoprofen Loxoprofen may decrease the excretion rate of Clofarabine which could result in a higher serum level. Lubiprostone Clofarabine may decrease the excretion rate of Lubiprostone which could result in a higher serum level. Lumiracoxib Lumiracoxib may decrease the excretion rate of Clofarabine which could result in a higher serum level. Macitentan Clofarabine may decrease the excretion rate of Macitentan which could result in a higher serum level. Magnesium The serum concentration of Magnesium can be decreased when it is combined with Clofarabine. Magnesium carbonate Clofarabine may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level. Magnesium chloride Clofarabine may decrease the excretion rate of Magnesium chloride which could result in a higher serum level. Magnesium hydroxide Clofarabine may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level. Magnesium trisilicate Clofarabine may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level. Mangafodipir Clofarabine may decrease the excretion rate of Mangafodipir which could result in a higher serum level. Manidipine Clofarabine may increase the hypotensive activities of Manidipine. Mannitol Mannitol may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. Maprotiline Clofarabine may decrease the excretion rate of Maprotiline which could result in a higher serum level. Maribavir Maribavir may decrease the excretion rate of Clofarabine which could result in a higher serum level. Measles virus vaccine The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Clofarabine. Mecamylamine The risk or severity of adverse effects can be increased when Clofarabine is combined with Mecamylamine. Mechlorethamine The risk or severity of adverse effects can be increased when Clofarabine is combined with Mechlorethamine. Meclofenamic acid Meclofenamic acid may decrease the excretion rate of Clofarabine which could result in a higher serum level. Medroxyprogesterone Medroxyprogesterone acetate may decrease the excretion rate of Clofarabine which could result in a higher serum level. Mefenamic acid Mefenamic acid may decrease the excretion rate of Clofarabine which could result in a higher serum level. Megestrol acetate Megestrol acetate may decrease the excretion rate of Clofarabine which could result in a higher serum level. Melatonin The excretion of Clofarabine can be decreased when combined with Melatonin. Meloxicam The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Meloxicam. Melphalan The risk or severity of adverse effects can be increased when Clofarabine is combined with Melphalan. Memantine Clofarabine may decrease the excretion rate of Memantine which could result in a higher serum level. Meningococcal The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Clofarabine. Meperidine Meperidine may decrease the excretion rate of Clofarabine which could result in a higher serum level. Mepivacaine The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Mepivacaine. Mepolizumab The risk or severity of adverse effects can be increased when Clofarabine is combined with Mepolizumab. Meprednisone The risk or severity of adverse effects can be increased when Clofarabine is combined with Meprednisone. Mercaptopurine The risk or severity of adverse effects can be increased when Clofarabine is combined with Mercaptopurine. Meropenem Clofarabine may decrease the excretion rate of Meropenem which could result in a higher serum level. Mesalazine Mesalazine may decrease the excretion rate of Clofarabine which could result in a higher serum level. Metamfetamine Clofarabine may decrease the excretion rate of Metamfetamine which could result in a higher serum level. Metamizole Metamizole may decrease the excretion rate of Clofarabine which could result in a higher serum level. Metaxalone Clofarabine may decrease the excretion rate of Metaxalone which could result in a higher serum level. Metformin Metformin may decrease the excretion rate of Clofarabine which could result in a higher serum level. Methadone Methadone may decrease the excretion rate of Clofarabine which could result in a higher serum level. Naproxen Naproxen may decrease the excretion rate of Clofarabine which could result in a higher serum level. Natalizumab The risk or severity of adverse effects can be increased when Clofarabine is combined with Natalizumab. Nateglinide Clofarabine may decrease the excretion rate of Nateglinide which could result in a higher serum level. Nebivolol The risk or severity of adverse effects can be increased when Clofarabine is combined with Nebivolol. Nedaplatin Clofarabine may decrease the excretion rate of Nedaplatin which could result in a higher serum level. Nedocromil Clofarabine may decrease the excretion rate of Nedocromil which could result in a higher serum level. Nefazodone Clofarabine may decrease the excretion rate of Nefazodone which could result in a higher serum level. Nelarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Nelarabine. Nelfinavir Nelfinavir may decrease the excretion rate of Clofarabine which could result in a higher serum level. Neomycin Clofarabine may decrease the excretion rate of Neomycin which could result in a higher serum level. Nesiritide The risk or severity of adverse effects can be increased when Clofarabine is combined with Nesiritide. Netilmicin Clofarabine may decrease the excretion rate of Netilmicin which could result in a higher serum level. Nialamide Nialamide may increase the orthostatic hypotensive activities of Clofarabine. Nicardipine The risk or severity of adverse effects can be increased when Nicardipine is combined with Clofarabine. Nicorandil Nicorandil may increase the hypotensive activities of Clofarabine. Nicotine The serum concentration of Clofarabine can be increased when it is combined with Nicotine. Nifedipine The risk or severity of adverse effects can be increased when Clofarabine is combined with Nifedipine. Nilotinib The risk or severity of adverse effects can be increased when Clofarabine is combined with Nilotinib. Nilutamide Clofarabine may decrease the excretion rate of Nilutamide which could result in a higher serum level. Nilvadipine The risk or severity of adverse effects can be increased when Clofarabine is combined with Nilvadipine. Nimesulide The risk or severity of bleeding can be increased when Nimesulide is combined with Clofarabine. Nimodipine The risk or severity of adverse effects can be increased when Nimodipine is combined with Clofarabine. Nisoldipine The risk or severity of adverse effects can be increased when Nisoldipine is combined with Clofarabine. Nitrendipine The risk or severity of adverse effects can be increased when Clofarabine is combined with Nitrendipine. Nitric Oxide The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Clofarabine. Nitrofurantoin Clofarabine may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level. Nitroglycerin The risk or severity of adverse effects can be increased when Clofarabine is combined with Nitroglycerin. Nitroprusside The risk or severity of adverse effects can be increased when Nitroprusside is combined with Clofarabine. Nitrous acid The risk or severity of adverse effects can be increased when Clofarabine is combined with Nitrous acid. Norepinephrine The serum concentration of Clofarabine can be increased when it is combined with Norepinephrine. Novobiocin The excretion of Clofarabine can be decreased when combined with Novobiocin. Nuvaxovid The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Clofarabine. Obinutuzumab The risk or severity of adverse effects can be increased when Clofarabine is combined with Obinutuzumab. Ocrelizumab Ocrelizumab may increase the immunosuppressive activities of Clofarabine. Octinoxate Clofarabine may decrease the excretion rate of Octinoxate which could result in a higher serum level. Ofatumumab The risk or severity of adverse effects can be increased when Clofarabine is combined with Ofatumumab. Olanzapine The risk or severity of adverse effects can be increased when Olanzapine is combined with Clofarabine. Olaparib The risk or severity of adverse effects can be increased when Clofarabine is combined with Olaparib. Olmesartan The risk or severity of adverse effects can be increased when Olmesartan is combined with Clofarabine. Olsalazine Olsalazine may decrease the excretion rate of Clofarabine which could result in a higher serum level. Omeprazole Omeprazole may decrease the excretion rate of Clofarabine which could result in a higher serum level. Opicapone The risk or severity of adverse effects can be increased when Clofarabine is combined with Opicapone. Opium Clofarabine may decrease the excretion rate of Opium which could result in a higher serum level. Oseltamivir Oseltamivir may decrease the excretion rate of Clofarabine which could result in a higher serum level. Osimertinib Osimertinib may decrease the excretion rate of Clofarabine which could result in a higher serum level. Oteseconazole The serum concentration of Clofarabine can be increased when it is combined with Oteseconazole. Ouabain The excretion of Clofarabine can be decreased when combined with Ouabain. Oxacillin Clofarabine may decrease the excretion rate of Oxacillin which could result in a higher serum level. Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Clofarabine. Pantoprazole The excretion of Clofarabine can be decreased when combined with Pantoprazole. Papaverine The risk or severity of adverse effects can be increased when Clofarabine is combined with Papaverine. Parecoxib Parecoxib may decrease the excretion rate of Clofarabine which could result in a higher serum level. Pargyline Pargyline may increase the orthostatic hypotensive activities of Clofarabine. Paritaprevir Paritaprevir may decrease the excretion rate of Clofarabine which could result in a higher serum level. Parnaparin The risk or severity of bleeding can be increased when Parnaparin is combined with Clofarabine. Paromomycin Paromomycin may decrease the excretion rate of Clofarabine which could result in a higher serum level. Patent Blue Clofarabine may decrease the excretion rate of Patent Blue which could result in a higher serum level. Pazopanib The risk or severity of adverse effects can be increased when Clofarabine is combined with Pazopanib. Pegaptanib Clofarabine may decrease the excretion rate of Pegaptanib which could result in a higher serum level. Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Clofarabine. Pegcetacoplan The risk or severity of adverse effects can be increased when Clofarabine is combined with Pegcetacoplan. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Clofarabine. Peginterferon The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Clofarabine. Peginterferon The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Clofarabine. Peginterferon The risk or severity of adverse effects can be increased when Clofarabine is combined with Peginterferon beta-1a. Pemetrexed The risk or severity of adverse effects can be increased when Clofarabine is combined with Pemetrexed. Penbutolol The risk or severity of adverse effects can be increased when Clofarabine is combined with Penbutolol. Penicillamine The risk or severity of adverse effects can be increased when Clofarabine is combined with Penicillamine. Pentaerythritol tetranitrate Clofarabine may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level. Pentamidine Pentamidine may decrease the excretion rate of Clofarabine which could result in a higher serum level. Pentastarch Clofarabine may decrease the excretion rate of Pentastarch which could result in a higher serum level. Pentetic acid Clofarabine may decrease the excretion rate of Pentetic acid which could result in a higher serum level. Pentobarbital Pentobarbital may increase the hypotensive activities of Clofarabine. Pentolinium Clofarabine may increase the hypotensive activities of Pentolinium. Pentosan polysulfate The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Clofarabine. Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Clofarabine. Pentoxifylline The risk or severity of bleeding can be increased when Pentoxifylline is combined with Clofarabine. Perindopril The risk or severity of adverse effects can be increased when Clofarabine is combined with Perindopril. Permethrin Clofarabine may decrease the excretion rate of Permethrin which could result in a higher serum level. Pertussis vaccine The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Clofarabine. Phenazopyridine Phenazopyridine may decrease the excretion rate of Clofarabine which could result in a higher serum level. Phenelzine Phenelzine may increase the orthostatic hypotensive activities of Clofarabine. Phenformin The serum concentration of Clofarabine can be increased when it is combined with Phenformin. Phenindione The risk or severity of bleeding can be increased when Phenindione is combined with Clofarabine. Phenobarbital Phenobarbital may increase the hypotensive activities of Clofarabine. Phenol The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Phenol. Phenoxybenzamine The serum concentration of Clofarabine can be increased when it is combined with Phenoxybenzamine. Phenprocoumon The risk or severity of bleeding can be increased when Phenprocoumon is combined with Clofarabine. Phentolamine The risk or severity of adverse effects can be increased when Clofarabine is combined with Phentolamine. Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Clofarabine. Phenylbutazone The excretion of Clofarabine can be decreased when combined with Phenylbutazone. Pholcodine Clofarabine may decrease the excretion rate of Pholcodine which could result in a higher serum level. Phosphoric acid Clofarabine may decrease the excretion rate of Phosphoric acid which could result in a higher serum level. Phylloquinone Clofarabine may decrease the excretion rate of Phylloquinone which could result in a higher serum level. Pibrentasvir Pibrentasvir may decrease the excretion rate of Clofarabine which could result in a higher serum level. Picosulfuric acid Clofarabine may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level. Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Clofarabine. Pinacidil Clofarabine may increase the hypotensive activities of Pinacidil. Pindolol The risk or severity of adverse effects can be increased when Clofarabine is combined with Pindolol. Piperacillin Piperacillin may decrease the excretion rate of Clofarabine which could result in a higher serum level. Piracetam Clofarabine may decrease the excretion rate of Piracetam which could result in a higher serum level. Piretanide Piretanide may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. Pirfenidone The risk or severity of adverse effects can be increased when Clofarabine is combined with Pirfenidone. Piroxicam The excretion of Clofarabine can be decreased when combined with Piroxicam. Pitolisant Clofarabine may decrease the excretion rate of Pitolisant which could result in a higher serum level. Plazomicin Clofarabine may decrease the excretion rate of Plazomicin which could result in a higher serum level. Plerixafor Clofarabine may decrease the excretion rate of Plerixafor which could result in a higher serum level. Polythiazide Polythiazide may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. Pomalidomide The risk or severity of adverse effects can be increased when Clofarabine is combined with Pomalidomide. Ponatinib The risk or severity of adverse effects can be increased when Clofarabine is combined with Ponatinib. Ponesimod The risk or severity of adverse effects can be increased when Clofarabine is combined with Ponesimod. Potassium Potassium may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. Potassium acetate Clofarabine may decrease the excretion rate of Potassium acetate which could result in a higher serum level. Potassium bicarbonate Clofarabine may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level. Potassium cation Potassium cation may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. Potassium chloride Clofarabine may decrease the excretion rate of Potassium chloride which could result in a higher serum level. Potassium citrate Potassium citrate may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. Potassium nitrate Clofarabine may decrease the excretion rate of Potassium nitrate which could result in a higher serum level. Potassium perchlorate Clofarabine may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level. Potassium sulfate Clofarabine may decrease the excretion rate of Potassium sulfate which could result in a higher serum level. Practolol Clofarabine may increase the hypotensive activities of Practolol. Pralatrexate The risk or severity of adverse effects can be increased when Clofarabine is combined with Pralatrexate. Pralidoxime Clofarabine may decrease the excretion rate of Pralidoxime which could result in a higher serum level. Pralsetinib Pralsetinib may decrease the excretion rate of Clofarabine which could result in a higher serum level. Pramipexole The risk or severity of adverse effects can be increased when Pramipexole is combined with Clofarabine. Pramocaine The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Pramocaine. Prasugrel The risk or severity of bleeding can be increased when Prasugrel is combined with Clofarabine. Pravastatin The excretion of Clofarabine can be decreased when combined with Pravastatin. Prazosin The risk or severity of adverse effects can be increased when Prazosin is combined with Clofarabine. Prednisolone The risk or severity of adverse effects can be increased when Clofarabine is combined with Prednisolone. Prednisone The risk or severity of adverse effects can be increased when Clofarabine is combined with Prednisone. Pregabalin Pregabalin may decrease the excretion rate of Clofarabine which could result in a higher serum level. Prilocaine The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Prilocaine. Primidone Primidone may increase the hypotensive activities of Clofarabine. Probenecid The serum concentration of Clofarabine can be increased when it is combined with Probenecid. Procainamide The serum concentration of Clofarabine can be increased when it is combined with Procainamide. Procaine The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Procaine. Procaine Clofarabine may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level. Procarbazine The risk or severity of adverse effects can be increased when Clofarabine is combined with Procarbazine. Progesterone The serum concentration of Clofarabine can be increased when it is combined with Progesterone. Promethazine Clofarabine may decrease the excretion rate of Promethazine which could result in a higher serum level. Propantheline Clofarabine may decrease the excretion rate of Propantheline which could result in a higher serum level. Proparacaine The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Proparacaine. Propiverine Clofarabine may decrease the excretion rate of Propiverine which could result in a higher serum level. Propofol The risk or severity of adverse effects can be increased when Clofarabine is combined with Propofol. Propoxycaine The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Propoxycaine. Propranolol The serum concentration of Clofarabine can be increased when it is combined with Propranolol. Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Clofarabine. Protein C The risk or severity of bleeding can be increased when Protein C is combined with Clofarabine. Protein S human The risk or severity of bleeding can be increased when Protein S human is combined with Clofarabine. Prucalopride Clofarabine may decrease the excretion rate of Prucalopride which could result in a higher serum level. Pyrantel Clofarabine may decrease the excretion rate of Pyrantel which could result in a higher serum level. Pyrazinamide Pyrazinamide may decrease the excretion rate of Clofarabine which could result in a higher serum level. Pyridoxine Pyridoxine may decrease the excretion rate of Clofarabine which could result in a higher serum level. Pyrithione Clofarabine may decrease the excretion rate of Pyrithione which could result in a higher serum level. Quetiapine The risk or severity of adverse effects can be increased when Clofarabine is combined with Quetiapine. Quinapril The risk or severity of adverse effects can be increased when Clofarabine is combined with Quinapril. Quinethazone Quinethazone may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. Quinidine The serum concentration of Clofarabine can be increased when it is combined with Quinidine. Quinine The serum concentration of Clofarabine can be increased when it is combined with Quinine. Rabeprazole Rabeprazole may decrease the excretion rate of Clofarabine which could result in a higher serum level. Rabies immune The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Clofarabine. Rabies virus The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Clofarabine. Rabies virus inactivated The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Clofarabine. Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Clofarabine. Ramelteon Clofarabine may decrease the excretion rate of Ramelteon which could result in a higher serum level. Ramipril The risk or severity of adverse effects can be increased when Ramipril is combined with Clofarabine. Ranitidine The serum concentration of Clofarabine can be increased when it is combined with Ranitidine. Ranolazine The serum concentration of Clofarabine can be increased when it is combined with Ranolazine. Rasagiline Rasagiline may increase the orthostatic hypotensive activities of Clofarabine. Ravulizumab The risk or severity of adverse effects can be increased when Clofarabine is combined with Ravulizumab. Regorafenib Regorafenib may decrease the excretion rate of Clofarabine which could result in a higher serum level. Remifentanil The risk or severity of adverse effects can be increased when Clofarabine is combined with Remifentanil. Rescinnamine Clofarabine may increase the hypotensive activities of Rescinnamine. Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Clofarabine. Resorcinol Clofarabine may decrease the excretion rate of Resorcinol which could result in a higher serum level. Reteplase The risk or severity of bleeding can be increased when Reteplase is combined with Clofarabine. Reviparin The risk or severity of bleeding can be increased when Reviparin is combined with Clofarabine. Ribavirin Clofarabine may decrease the excretion rate of Ribavirin which could result in a higher serum level. Ribostamycin Clofarabine may decrease the excretion rate of Ribostamycin which could result in a higher serum level. Rifampicin The excretion of Clofarabine can be decreased when combined with Rifampicin. Rilmenidine Clofarabine may increase the hypotensive activities of Rilmenidine. Rilonacept The risk or severity of adverse effects can be increased when Clofarabine is combined with Rilonacept. Rilpivirine Rilpivirine may decrease the excretion rate of Clofarabine which could result in a higher serum level. Riociguat The risk or severity of adverse effects can be increased when Clofarabine is combined with Riociguat. Ripretinib Ripretinib may decrease the excretion rate of Clofarabine which could result in a higher serum level. Risankizumab The risk or severity of adverse effects can be increased when Clofarabine is combined with Risankizumab. Risperidone Clofarabine may increase the hypotensive activities of Risperidone. Ritonavir Ritonavir may decrease the excretion rate of Clofarabine which could result in a higher serum level. Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Clofarabine. Rivaroxaban Clofarabine may decrease the excretion rate of Rivaroxaban which could result in a higher serum level. Rizatriptan Clofarabine may decrease the excretion rate of Rizatriptan which could result in a higher serum level. Rofecoxib Rofecoxib may decrease the excretion rate of Clofarabine which could result in a higher serum level. Roflumilast Roflumilast may increase the immunosuppressive activities of Clofarabine. Rolapitant Rolapitant may decrease the excretion rate of Clofarabine which could result in a higher serum level. Ropeginterferon The risk or severity of adverse effects can be increased when Clofarabine is combined with Ropeginterferon alfa-2b. Ropinirole The risk or severity of adverse effects can be increased when Ropinirole is combined with Clofarabine. Ropivacaine The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Ropivacaine. Rosiglitazone Rosiglitazone may decrease the excretion rate of Clofarabine which could result in a higher serum level. Rosuvastatin The excretion of Clofarabine can be decreased when combined with Rosuvastatin. Rotavirus vaccine The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Clofarabine. Rotigotine The risk or severity of adverse effects can be increased when Clofarabine is combined with Rotigotine. Roxadustat The serum concentration of Clofarabine can be increased when it is combined with Roxadustat. Rubella virus vaccine The risk or severity of infection can be increased when Rubella virus vaccine is combined with Clofarabine. Rucaparib Rucaparib may decrease the excretion rate of Clofarabine which could result in a higher serum level. Ruxolitinib The risk or severity of adverse effects can be increased when Clofarabine is combined with Ruxolitinib. Sacubitril The risk or severity of adverse effects can be increased when Clofarabine is combined with Sacubitril. Safinamide Safinamide may increase the orthostatic hypotensive activities of Clofarabine. Salbutamol Clofarabine may decrease the excretion rate of Salbutamol which could result in a higher serum level. Salicylamide Salicylamide may decrease the excretion rate of Clofarabine which could result in a higher serum level. Salicylic acid The excretion of Clofarabine can be decreased when combined with Salicylic acid. Salmeterol The serum concentration of Clofarabine can be increased when it is combined with Salmeterol. Salmon calcitonin Salmon calcitonin may decrease the excretion rate of Clofarabine which could result in a higher serum level. Salsalate Salsalate may decrease the excretion rate of Clofarabine which could result in a higher serum level. Saquinavir Saquinavir may decrease the excretion rate of Clofarabine which could result in a higher serum level. Sarilumab The risk or severity of adverse effects can be increased when Clofarabine is combined with Sarilumab. Satralizumab The risk or severity of adverse effects can be increased when Clofarabine is combined with Satralizumab. Saxagliptin Clofarabine may decrease the excretion rate of Saxagliptin which could result in a higher serum level. Secobarbital Secobarbital may increase the hypotensive activities of Clofarabine. Secukinumab The risk or severity of adverse effects can be increased when Clofarabine is combined with Secukinumab. Selegiline Selegiline may increase the orthostatic hypotensive activities of Clofarabine. Selenious acid Clofarabine may decrease the excretion rate of Selenious acid which could result in a higher serum level. Selenium Clofarabine may decrease the excretion rate of Selenium which could result in a higher serum level. Selexipag Clofarabine may increase the hypotensive activities of Selexipag. Sevoflurane The risk or severity of adverse effects can be increased when Clofarabine is combined with Sevoflurane. Sibutramine Clofarabine may decrease the excretion rate of Sibutramine which could result in a higher serum level. Sildenafil The risk or severity of hypotension can be increased when Sildenafil is combined with Clofarabine. Siltuximab The risk or severity of adverse effects can be increased when Clofarabine is combined with Siltuximab. Simeprevir Simeprevir may decrease the excretion rate of Clofarabine which could result in a higher serum level. Siponimod The risk or severity of adverse effects can be increased when Clofarabine is combined with Siponimod. Sipuleucel-T The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Clofarabine. You Might Also Read Which Drugs Are Use For Destroy the Sex? Sirolimus The risk or severity of adverse effects can be increased when Clofarabine is combined with Sirolimus. Sitagliptin Clofarabine may decrease the excretion rate of Sitagliptin which could result in a higher serum level. Sitaxentan Clofarabine may increase the hypotensive activities of Sitaxentan. Smallpox The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Clofarabine. Sodium acetate Clofarabine may decrease the excretion rate of Sodium acetate which could result in a higher serum level. Sodium aurothiomalate Clofarabine may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level. Sodium citrate The risk or severity of bleeding can be increased when Sodium citrate is combined with Clofarabine. Sodium ferric The risk or severity of hypotension can be increased when Sodium ferric gluconate complex is combined with Clofarabine. Sodium fluoride Clofarabine may decrease the excretion rate of Sodium fluoride which could result in a higher serum level. Sodium sulfate Clofarabine may decrease the excretion rate of Sodium sulfate which could result in a higher serum level. Sofosbuvir Clofarabine may decrease the excretion rate of Sofosbuvir which could result in a higher serum level. Solriamfetol Clofarabine may decrease the excretion rate of Solriamfetol which could result in a higher serum level. Sorafenib The risk or severity of adverse effects can be increased when Sorafenib is combined with Clofarabine. Sorbitol Clofarabine may decrease the excretion rate of Sorbitol which could result in a higher serum level. Sotagliflozin Sotagliflozin may decrease the excretion rate of Clofarabine which could result in a higher serum level. Sotalol The risk or severity of adverse effects can be increased when Sotalol is combined with Clofarabine. Spesolimab The risk or severity of adverse effects can be increased when Clofarabine is combined with Spesolimab. Spirapril Clofarabine may increase the hypotensive activities of Spirapril. Spironolactone Spironolactone may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. Stiripentol The excretion of Clofarabine can be decreased when combined with Stiripentol. Streptokinase The risk or severity of adverse effects can be increased when Streptokinase is combined with Clofarabine. Streptomycin Clofarabine may decrease the excretion rate of Streptomycin which could result in a higher serum level. Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Clofarabine. Strontium chloride Clofarabine may decrease the excretion rate of Strontium chloride which could result in a higher serum level. Sucralfate Sucralfate may decrease the excretion rate of Clofarabine which could result in a higher serum level. Sufentanil The risk or severity of adverse effects can be increased when Clofarabine is combined with Sufentanil. Sulbactam Clofarabine may decrease the excretion rate of Sulbactam which could result in a higher serum level. Sulfadiazine Sulfadiazine may decrease the excretion rate of Clofarabine which could result in a higher serum level. Sulfamethoxazole The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Clofarabine. Sulfasalazine The risk or severity of adverse effects can be increased when Clofarabine is combined with Sulfasalazine. Sulfinpyrazone The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Clofarabine. Sulindac Sulindac may decrease the excretion rate of Clofarabine which could result in a higher serum level. Sulodexide The risk or severity of bleeding can be increased when Sulodexide is combined with Clofarabine. Sumatriptan Clofarabine may decrease the excretion rate of Sumatriptan which could result in a higher serum level. Sunitinib The risk or severity of adverse effects can be increased when Clofarabine is combined with Sunitinib. Estrogens, A Clofarabine may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level. Synthetic Conjugated Clofarabine may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level. Tacrolimus Tacrolimus may increase the immunosuppressive activities of Clofarabine. Tadalafil Clofarabine may decrease the excretion rate of Tadalafil which could result in a higher serum level. Tafamidis The serum concentration of Clofarabine can be increased when it is combined with Tafamidis. Tafenoquine The serum concentration of Clofarabine can be increased when it is combined with Tafenoquine. Tamsulosin The risk or severity of adverse effects can be increased when Clofarabine is combined with Tamsulosin. Tasimelteon Clofarabine may decrease the excretion rate of Tasimelteon which could result in a higher serum level. Taurocholic acid The excretion of Clofarabine can be decreased when combined with Taurocholic acid. Tazobactam The excretion of Clofarabine can be decreased when combined with Tazobactam. Technetium Clofarabine may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level. Technetium Clofarabine may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level. Technetium Clofarabine may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level. Technetium Clofarabine may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level. Tedizolid phosphate The risk or severity of myelosuppression can be increased when Clofarabine is combined with Tedizolid phosphate. Teduglutide Clofarabine may decrease the excretion rate of Teduglutide which could result in a higher serum level. Tegafur Clofarabine may decrease the excretion rate of Tegafur which could result in a higher serum level. Telavancin Clofarabine may decrease the excretion rate of Telavancin which could result in a higher serum level. Telmisartan Telmisartan may decrease the excretion rate of Clofarabine which could result in a higher serum level. Temazepam Temazepam may decrease the excretion rate of Clofarabine which could result in a higher serum level. Temozolomide The risk or severity of adverse effects can be increased when Clofarabine is combined with Temozolomide. Temsirolimus The risk or severity of adverse effects can be increased when Clofarabine is combined with Temsirolimus. Tenecteplase The risk or severity of bleeding can be increased when Tenecteplase is combined with Clofarabine. Teniposide The risk or severity of adverse effects can be increased when Teniposide is combined with Clofarabine. Tenofovir alafenamide Tenofovir alafenamide may decrease the excretion rate of Clofarabine which could result in a higher serum level. Tenofovir disoproxil Tenofovir disoproxil may decrease the excretion rate of Clofarabine which could result in a higher serum level. Tenoxicam The excretion of Clofarabine can be decreased when combined with Tenoxicam. Tepotinib Tepotinib may decrease the excretion rate of Clofarabine which could result in a higher serum level. Teprotumumab The risk or severity of adverse effects can be increased when Clofarabine is combined with Teprotumumab. Terazosin The risk or severity of adverse effects can be increased when Clofarabine is combined with Terazosin. Terbutaline Clofarabine may decrease the excretion rate of Terbutaline which could result in a higher serum level. Teriflunomide The risk or severity of adverse effects can be increased when Clofarabine is combined with Teriflunomide. Testolactone Clofarabine may decrease the excretion rate of Testolactone which could result in a higher serum level. Testosterone The excretion of Clofarabine can be increased when combined with Testosterone. Testosterone The excretion of Clofarabine can be increased when combined with Testosterone cypionate. Testosterone The excretion of Clofarabine can be increased when combined with Testosterone enanthate. Testosterone Clofarabine may decrease the excretion rate of Testosterone propionate which could result in a higher serum level. Testosterone Clofarabine may decrease the excretion rate of Testosterone undecanoate which could result in a higher serum level. Tetracaine The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Tetracaine. Tetracycline The excretion of Clofarabine can be decreased when combined with Tetracycline. Tetradecyl hydrogen ) Clofarabine may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level. Thalidomide The risk or severity of adverse effects can be increased when Clofarabine is combined with Thalidomide. Thiabendazole Clofarabine may decrease the excretion rate of Thiabendazole which could result in a higher serum level. Thiamine The serum concentration of Clofarabine can be increased when it is combined with Thiamine. Thiamylal Thiamylal may increase the hypotensive activities of Clofarabine. Thiethylperazine Thiethylperazine may decrease the excretion rate of Clofarabine which could result in a higher serum level. Thiopental Thiopental may increase the hypotensive activities of Clofarabine. Thioridazine The risk or severity of adverse effects can be increased when Clofarabine is combined with Thioridazine. Thiotepa The risk or severity of adverse effects can be increased when Clofarabine is combined with Thiotepa. Tiaprofenic acid Tiaprofenic acid may decrease the excretion rate of Clofarabine which could result in a higher serum level. Ticagrelor The risk or severity of bleeding can be increased when Ticagrelor is combined with Clofarabine. Tick-borne encephalitis The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Clofarabine. Ticlopidine The risk or severity of bleeding can be increased when Ticlopidine is combined with Clofarabine. Tiludronic acid Clofarabine may decrease the excretion rate of Tiludronic acid which could result in a higher serum level. Timolol The risk or severity of adverse effects can be increased when Timolol is combined with Clofarabine. Tinidazole Clofarabine may decrease the excretion rate of Tinidazole which could result in a higher serum level. Tinzaparin The risk or severity of bleeding can be increased when Tinzaparin is combined with Clofarabine. Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Clofarabine. Tiopronin Clofarabine may decrease the excretion rate of Tiopronin which could result in a higher serum level. Tiotropium Clofarabine may decrease the excretion rate of Tiotropium which could result in a higher serum level. Tirofiban The risk or severity of bleeding can be increased when Tirofiban is combined with Clofarabine. Tivozanib Tivozanib may decrease the excretion rate of Clofarabine which could result in a higher serum level. Tixocortol The risk or severity of adverse effects can be increased when Clofarabine is combined with Tixocortol. Tizanidine The risk or severity of adverse effects can be increased when Clofarabine is combined with Tizanidine. Tobramycin Clofarabine may decrease the excretion rate of Tobramycin which could result in a higher serum level. Tocilizumab The risk or severity of adverse effects can be increased when Clofarabine is combined with Tocilizumab. Tocopherol Clofarabine may decrease the excretion rate of Tocopherol which could result in a higher serum level. Tofacitinib Clofarabine may increase the immunosuppressive activities of Tofacitinib. Tolazamide Clofarabine may decrease the excretion rate of Tolazamide which could result in a higher serum level. Tolazoline The risk or severity of adverse effects can be increased when Clofarabine is combined with Tolazoline. Tolbutamide Clofarabine may decrease the excretion rate of Tolbutamide which could result in a higher serum level. Tolcapone The risk or severity of adverse effects can be increased when Tolcapone is combined with Clofarabine. Tolfenamic acid Tolfenamic acid may decrease the excretion rate of Clofarabine which could result in a higher serum level. Tolmetin Tolmetin may decrease the excretion rate of Clofarabine which could result in a higher serum level. Tolterodine Clofarabine may decrease the excretion rate of Tolterodine which could result in a higher serum level. Tolvaptan Tolvaptan may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. Topiramate Topiramate may decrease the excretion rate of Clofarabine which could result in a higher serum level. Topotecan The risk or severity of adverse effects can be increased when Clofarabine is combined with Topotecan. Torasemide Torasemide may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Clofarabine. Trabectedin The risk or severity of adverse effects can be increased when Clofarabine is combined with Trabectedin. Tramadol Tramadol may decrease the excretion rate of Clofarabine which could result in a higher serum level. Trametinib Clofarabine may decrease the excretion rate of Trametinib which could result in a higher serum level. Trandolapril The risk or severity of adverse effects can be increased when Trandolapril is combined with Clofarabine. Tranylcypromine Tranylcypromine may increase the orthostatic hypotensive activities of Clofarabine. Trastuzumab Trastuzumab may increase the neutropenic activities of Clofarabine. Trastuzumab The risk or severity of adverse effects can be increased when Clofarabine is combined with Trastuzumab emtansine. Treprostinil Clofarabine may increase the hypotensive activities of Treprostinil. Tretinoin The risk or severity of adverse effects can be increased when Clofarabine is combined with Tretinoin. Triamcinolone The risk or severity of adverse effects can be increased when Triamcinolone is combined with Clofarabine. Triamterene Triamterene may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. Triazolam Clofarabine may decrease the excretion rate of Triazolam which could result in a higher serum level. Trichlormethiazide Trichlormethiazide may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. Triethylenetetramine Clofarabine may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level. Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Clofarabine. Triflusal The risk or severity of bleeding can be increased when Triflusal is combined with Clofarabine. Trilaciclib The serum concentration of Clofarabine can be increased when it is combined with Trilaciclib. Trilostane The risk or severity of adverse effects can be increased when Clofarabine is combined with Trilostane. Trimebutine Clofarabine may decrease the excretion rate of Trimebutine which could result in a higher serum level. Trimethaphan Clofarabine may increase the hypotensive activities of Trimethaphan. Trimethoprim The serum concentration of Clofarabine can be increased when it is combined with Trimethoprim. Trimetrexate Clofarabine may decrease the excretion rate of Trimetrexate which could result in a higher serum level. Tropisetron Clofarabine may decrease the excretion rate of Tropisetron which could result in a higher serum level. Tucatinib The serum concentration of Clofarabine can be increased when it is combined with Tucatinib. Typhoid vaccine The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Clofarabine. Typhoid Vaccine The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Clofarabine. Typhoid Vi The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Clofarabine. Udenafil The risk or severity of hypotension can be increased when Udenafil is combined with Clofarabine. Upadacitinib The risk or severity of adverse effects can be increased when Clofarabine is combined with Upadacitinib. Urokinase The risk or severity of bleeding can be increased when Urokinase is combined with Clofarabine. Vaborbactam Clofarabine may decrease the excretion rate of Vaborbactam which could result in a higher serum level. Valaciclovir Valaciclovir may decrease the excretion rate of Clofarabine which could result in a higher serum level. Valbenazine Clofarabine may decrease the excretion rate of Valbenazine which could result in a higher serum level. Valdecoxib Valdecoxib may decrease the excretion rate of Clofarabine which could result in a higher serum level. Valganciclovir Clofarabine may decrease the excretion rate of Valganciclovir which could result in a higher serum level. Valproic acid The excretion of Clofarabine can be decreased when combined with Valproic acid. Valsartan The risk or severity of adverse effects can be increased when Valsartan is combined with Clofarabine. Vancomycin Clofarabine may decrease the excretion rate of Vancomycin which could result in a higher serum level. Vandetanib The serum concentration of Clofarabine can be increased when it is combined with Vandetanib. Vardenafil The risk or severity of hypotension can be increased when Vardenafil is combined with Clofarabine. Varenicline The serum concentration of Clofarabine can be increased when it is combined with Varenicline. Varicella zoster The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Clofarabine. Varicella zoster The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Clofarabine. Vedolizumab The risk or severity of adverse effects can be increased when Clofarabine is combined with Vedolizumab. Velpatasvir Velpatasvir may decrease the excretion rate of Clofarabine which could result in a higher serum level. Vemurafenib Vemurafenib may decrease the excretion rate of Clofarabine which could result in a higher serum level. Venetoclax Venetoclax may decrease the excretion rate of Clofarabine which could result in a higher serum level. Venlafaxine Venlafaxine may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. Verapamil The risk or severity of adverse effects can be increased when Clofarabine is combined with Verapamil. Vericiguat The risk or severity of adverse effects can be increased when Clofarabine is combined with Vericiguat. Vibrio cholerae The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Clofarabine. Vilanterol The risk or severity of adverse effects can be increased when Clofarabine is combined with Vilanterol. Viloxazine Clofarabine may decrease the excretion rate of Viloxazine which could result in a higher serum level. Vinblastine The risk or severity of adverse effects can be increased when Vinblastine is combined with Clofarabine. Vincristine The risk or severity of adverse effects can be increased when Vincristine is combined with Clofarabine. Vindesine The risk or severity of adverse effects can be increased when Vindesine is combined with Clofarabine. Vinorelbine The risk or severity of adverse effects can be increased when Vinorelbine is combined with Clofarabine. Vismodegib Vismodegib may decrease the excretion rate of Clofarabine which could result in a higher serum level. Voclosporin The risk or severity of adverse effects can be increased when Clofarabine is combined with Voclosporin. Vorapaxar The risk or severity of bleeding can be increased when Vorapaxar is combined with Clofarabine. Vorinostat The risk or severity of adverse effects can be increased when Clofarabine is combined with Vorinostat. Vortioxetine Clofarabine may decrease the excretion rate of Vortioxetine which could result in a higher serum level. Voxilaprevir Voxilaprevir may decrease the excretion rate of Clofarabine which could result in a higher serum level. Warfarin Clofarabine may decrease the excretion rate of Warfarin which could result in a higher serum level. Pregnancy and Lactation FDA Pregnancy Category D Pregnancy Collar (clofarabine) may cause fetal harm when administered to a pregnant woman. Clofarabine was teratogenic in rats and rabbits. Developmental toxicity (reduced fetal body weight and increased post-implantation loss) and increased incidences of malformations and variations (gross external, soft tissue, skeletal and retarded ossification) were observed in rats receiving 54 mg/m2 /day (approximately equivalent to the recommended clinical dose on an mg/m2 basis), and in rabbits receiving 12 mg/m2 /day (approximately 23% of the recommended clinical dose on an mg/m2 basis). There are no adequate and well-controlled studies on pregnant women using clofarabine. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with clofarabine. All patients should be advised to use effective contraceptive measures to prevent pregnancy. Lactation It is not known whether clofarabine or its metabolites are excreted in human milk. Because of the potential for tumorigenicity shown for clofarabine in animal studies and the potential for serious adverse reactions, women treated with clofarabine should not nurse. Female patients should be advised to avoid breastfeeding during treatment with Clolar. How should this medicine be used? Clofarabine comes as a solution to be injected into a vein. Clofarabine is administered by a doctor or nurse. It is usually given once a day for 5 days in a row. This dosing cycle may be repeated once every 2 to 6 weeks, depending on your response to the medication. It will take at least 2 hours for you to receive each dose of clofarabine. Tell your doctor or another healthcare provider right away if you feel anxious or restless while you are receiving the medication. What special precautions should I follow? Before using clofarabine, tell your doctor and pharmacist if you are allergic to clofarabine or any other medications. tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention medications for high blood pressure and heart disease. Your doctor may need to change the doses of your medications or monitor you carefully for side effects. tell your doctor if you have or have ever had kidney or liver disease. tell your doctor if you are pregnant or plan to become pregnant. Clofarabine may harm the fetus. You should use birth control to prevent pregnancy during your treatment with clofarabine. Talk to your doctor about the types of birth control that will work for you. If you become pregnant while using clofarabine, call your doctor. tell your doctor if you are breastfeeding. You should not breastfeed during your treatment with clofarabine. if you are having surgery, including dental surgery, tell the doctor or dentist that you are receiving clofarabine. you should know that clofarabine may cause a skin condition called hand-foot syndrome. If you develop this condition, you may experience tingling of the hands and feet, and then reddening dryness, and flaking of the skin on the hands and feet. If this happens, ask your doctor to recommend a lotion that you can apply to these areas. You will need to apply the lotion lightly and avoid rubbing the areas forcefully. Your doctor may also prescribe medication to relieve these symptoms. References https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021673s024lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-673_Clolar.cfm https://www.cancer.gov/about-cancer/treatment/drugs/clofarabine https://go.drugbank.com/drugs/DB00631 https://en.wikipedia.org/wiki/Clofarabine https://medlineplus.gov/druginfo/meds/a607012.html https://www.drugs.com/mtm/clofarabine.html https://pubchem.ncbi.nlm.nih.gov/compound/Clofarabin https://pubchem.ncbi.nlm.nih.gov/compound/Clofarabine-triphosphate#section=Chemical-Co-Occurrences-in-Literature https://www.webmd.com/drugs/2/drug-92460/clofarabine-intravenous/details/list-contraindications ChemIDplus LICENSE https://www.nlm.nih.gov/copyright.html Clofarabine [USAN:INN:BAN] https://chem.nlm.nih.gov/chemidplus/sid/0123318821 ChemIDplus Chemical Information Classification https://chem.nlm.nih.gov/chemidplus/ DrugBank https://www.drugbank.ca/legal/terms_of_use Clofarabine https://www.drugbank.ca/drugs/DB00631 EPA DSSTox LICENSE https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources Clofarabine https://comptox.epa.gov/dashboard/DTXSID5046437 CompTox Chemicals Dashboard Chemical Lists https://comptox.epa.gov/dashboard/chemical-lists/ European Chemicals Agency (ECHA) https://echa.europa.eu/web/guest/legal-notice (2R,3R,4S,5R)-5-(6-amino-2-chloro-9H-purin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol https://echa.europa.eu/information-on-chemicals (2R,3R,4S,5R)-5-(6-amino-2-chloro-9H-purin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/164482 FDA Global Substance Registration System (GSRS) https://www.fda.gov/about-fda/about-website/website-policies#linking CLOFARABINE https://gsrs.ncats.nih.gov/ginas/app/beta/substances/762RDY0Y2H Human Metabolome Database (HMDB) http://www.hmdb.ca/citing Clofarabine http://www.hmdb.ca/metabolites/HMDB0014769 HMDB0014769_msms_374211 https://hmdb.ca/metabolites/HMDB0014769#spectra ChEBI Clofarabine http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:681569 ChEBI Ontology http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology FDA Pharm Classes https://www.fda.gov/about-fda/about-website/website-policies#linking CLOFARABINE https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm FDA Pharmacological Classification https://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm LiverTox LICENSE https://www.nlm.nih.gov/copyright.html Clofarabine https://www.ncbi.nlm.nih.gov/books/n/livertox/Clofarabine/ NCI Thesaurus (NCIt) https://www.cancer.gov/policies/copyright-reuse https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C26638 NCI Thesaurus Tree https://ncit.nci.nih.gov ChEMBL http://www.ebi.ac.uk/Information/termsofuse.html https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1750/ ChEMBL Protein Target Tree https://www.ebi.ac.uk/chembl/g/#browse/targets Comparative Toxicogenomics Database (CTD) http://ctdbase.org/about/legal.jsp https://ctdbase.org/detail.go?type=chem&acc=D000077866 Drug Gene Interaction database (DGIdb) http://www.dgidb.org/downloads https://www.dgidb.org/drugs/CLOFARABINE IUPHAR/BPS Guide to PHARMACOLOGY https://www.guidetopharmacology.org/about.jsp#license https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6802 Guide to Pharmacology Target Classification https://www.guidetopharmacology.org/targets.jsp Therapeutic Target Database (TTD) Clofarabine http://idrblab.net/ttd/data/drug/details/D0R5RR ClinicalTrials.gov https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use https://clinicaltrials.gov/ DailyMed LICENSE https://www.nlm.nih.gov/copyright.html CLOFARABINE https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=CLOFARABINE Drug Induced Liver Injury Rank (DILIrank) Dataset https://www.fda.gov/about-fda/about-website/website-policies#linking clofarabine https://www.fda.gov/science-research/liver-toxicity-knowledge-base-ltkb/drug-induced-liver-injury-rank-dilirank-dataset European Medicines Agency (EMA) https://www.ema.europa.eu/en/about-us/legal-notice Evoltra (EMEA/H/C/000613) https://www.ema.europa.eu/en/medicines/human/EPAR/evoltra EU Clinical Trials Register https://www.clinicaltrialsregister.eu/ FDA Orange Book https://www.fda.gov/about-fda/about-website/website-policies#linking https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book WHO Anatomical Therapeutic Chemical (ATC) Classification https://www.whocc.no/copyright_disclaimer/ https://www.whocc.no/atc/ ATC Code https://www.whocc.no/atc_ddd_index/ National Drug Code (NDC) Directory https://www.fda.gov/about-fda/about-website/website-policies#linking CLOFARABINE https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory MassBank of North America (MoNA) LICENSE The content of the MoNA database is licensed under CC BY 4.0. https://mona.fiehnlab.ucdavis.edu/documentation/license Clofarabine https://mona.fiehnlab.ucdavis.edu/spectra/browse?query=compound.metaData%3Dq%3D%27name%3D%3D%22InChIKey%22%20and%20value%3D%3D%22WDDPHFBMKLOVOX-AYQXTPAHSA-N%22%27 NCI Cancer Drugs LICENSE https://www.cancer.gov/policies/copyright-reuse Clofarabine https://www.cancer.gov/about-cancer/treatment/drugs/clofarabine NLM RxNorm Terminology. https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html clofarabine https://rxnav.nlm.nih.gov/id/rxnorm/44151 Protein Data Bank in Europe (PDBe) http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/CFB RCSB Protein Data Bank (RCSB PDB) https://www.rcsb.org/pages/policies https://www.rcsb.org/ Springer Nature https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=20051260-195277142 https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=20051260-195290908 Thieme Chemistry https://creativecommons.org/licenses/by-nc-nd/4.0/ https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=20051260-195293037 Wikidata LICENSE CCZero https://creativecommons.org/publicdomain/zero/1.0/ Clofarabine https://www.wikidata.org/wiki/Q5134875 Medical Subject Headings (MeSH) https://www.nlm.nih.gov/copyright.html Clofarabine https://www.ncbi.nlm.nih.gov/mesh/2028157 MeSH Tree http://www.nlm.nih.gov/mesh/meshhome.html Antimetabolites, Antineoplastic https://www.ncbi.nlm.nih.gov/mesh/68000964 PubChem https://pubchem.ncbi.nlm.nih.gov PFAS and Fluorinated Compounds in PubChem https://gitlab.lcsb.uni.lu/eci/pubchem-docs/-/raw/main/pfas-tree/PFAS_Tree.pdf?inline=false KEGG LICENSE Academic users may freely use the KEGG website. Non-academic use of KEGG generally requires a commercial license https://www.kegg.jp/kegg/legal.html Therapeutic category of drugs in Japan http://www.genome.jp/kegg-bin/get_htext?br08301.keg Anatomical Therapeutic Chemical (ATC) classification http://www.genome.jp/kegg-bin/get_htext?br08303.keg Target-based classification of drugs http://www.genome.jp/kegg-bin/get_htext?br08310.keg Drug Groups http://www.genome.jp/kegg-bin/get_htext?br08330.keg Drug Classes http://www.genome.jp/kegg-bin/get_htext?br08332.keg UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS) GHS Classification Tree http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html NORMAN Suspect List Exchange LICENSE Data: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0 https://creativecommons.org/licenses/by/4.0/ NORMAN Suspect List Exchange Classification https://www.norman-network.com/nds/SLE/ PATENTSCOPE (WIPO) SID 388760107 https://pubchem.ncbi.nlm.nih.gov/substance/388760107 NCBI https://www.ncbi.nlm.nih.gov/projects/linkout Show More